<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8431379</article-id><article-id pub-id-type="doi">10.3390/ijms22179118</article-id><article-id pub-id-type="publisher-id">ijms-22-09118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Wentao</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Zixuan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Bin</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1077-8014</contrib-id><name><surname>Zhang</surname><given-names>Wenxiang</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9251-708X</contrib-id><name><surname>Liu</surname><given-names>Chang</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3809-1062</contrib-id><name><surname>Chen</surname><given-names>Siyu</given-names></name><xref rid="c1-ijms-22-09118" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2140-9705</contrib-id><name><surname>Song</surname><given-names>Mingming</given-names></name><xref rid="c1-ijms-22-09118" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Juh&#x000e1;sz</surname><given-names>&#x000c1;d&#x000e1;m</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Csap&#x000f3;</surname><given-names>Edit</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-22-09118">School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China; <email>3320031498@stu.cpu.edu.cn</email> (W.X.); <email>3219030715@stu.cpu.edu.cn</email> (Z.T.); <email>3220030444@stu.cpu.edu.cn</email> (B.Z.); <email>wenxiangzhang@cpu.edu.cn</email> (W.Z.); <email>changliu@cpu.edu.cn</email> (C.L.)</aff><author-notes><corresp id="c1-ijms-22-09118"><label>*</label>Correspondence: <email>siyuchen@cpu.edu.cn</email> (S.C.); <email>1520210049@cpu.edu.cn</email> (M.S.); Tel.: +86-25-8618-5645 (M.S.)</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>8</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2021</year></pub-date><volume>22</volume><issue>17</issue><elocation-id>9118</elocation-id><history><date date-type="received"><day>28</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cancer is one of the primary causes of worldwide human deaths. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. The emergence of nanotechnology has had a profound impact on general clinical treatment. The application of nanotechnology has facilitated the development of nano-drug delivery systems (NDDSs) that are highly tumor selective and allow for the slow release of active anticancer drugs. In recent years, vehicles such as liposomes, dendrimers and polymer nanomaterials have been considered promising carriers for tumor-specific drug delivery, reducing toxicity and improving biocompatibility. Among them, polymer nanoparticles (NPs) are one of the most innovative methods of non-invasive drug delivery. Here, we review the application of polymer NPs in drug delivery, gene therapy, and early diagnostics for cancer therapy.</p></abstract><kwd-group><kwd>polymer nanocarriers</kwd><kwd>cancer therapy</kwd><kwd>drug delivery</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-22-09118"><title>1. Introduction</title><p>Cancer is still the second leading cause of death globally, and its death toll exceeds the combined deaths from human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria [<xref rid="B1-ijms-22-09118" ref-type="bibr">1</xref>,<xref rid="B2-ijms-22-09118" ref-type="bibr">2</xref>,<xref rid="B3-ijms-22-09118" ref-type="bibr">3</xref>,<xref rid="B4-ijms-22-09118" ref-type="bibr">4</xref>]. In 2020, GLOBOCAN estimated that 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred worldwide [<xref rid="B5-ijms-22-09118" ref-type="bibr">5</xref>,<xref rid="B6-ijms-22-09118" ref-type="bibr">6</xref>]. Cancer includes a series of diseases caused by the uncontrolled growth of malignant cells, which may invade or spread to other parts of the body [<xref rid="B7-ijms-22-09118" ref-type="bibr">7</xref>,<xref rid="B8-ijms-22-09118" ref-type="bibr">8</xref>]. Thus far, many strategies have been developed for cancer treatment, including surgery [<xref rid="B9-ijms-22-09118" ref-type="bibr">9</xref>,<xref rid="B10-ijms-22-09118" ref-type="bibr">10</xref>], radiation therapy [<xref rid="B11-ijms-22-09118" ref-type="bibr">11</xref>,<xref rid="B12-ijms-22-09118" ref-type="bibr">12</xref>,<xref rid="B13-ijms-22-09118" ref-type="bibr">13</xref>], chemotherapy [<xref rid="B14-ijms-22-09118" ref-type="bibr">14</xref>,<xref rid="B15-ijms-22-09118" ref-type="bibr">15</xref>,<xref rid="B16-ijms-22-09118" ref-type="bibr">16</xref>,<xref rid="B17-ijms-22-09118" ref-type="bibr">17</xref>], targeted therapy [<xref rid="B18-ijms-22-09118" ref-type="bibr">18</xref>,<xref rid="B19-ijms-22-09118" ref-type="bibr">19</xref>,<xref rid="B20-ijms-22-09118" ref-type="bibr">20</xref>], hormonal therapy [<xref rid="B21-ijms-22-09118" ref-type="bibr">21</xref>,<xref rid="B22-ijms-22-09118" ref-type="bibr">22</xref>], and immunotherapy [<xref rid="B23-ijms-22-09118" ref-type="bibr">23</xref>,<xref rid="B24-ijms-22-09118" ref-type="bibr">24</xref>], or a combination of these options [<xref rid="B25-ijms-22-09118" ref-type="bibr">25</xref>,<xref rid="B26-ijms-22-09118" ref-type="bibr">26</xref>]. As a result of all these treatments, the incidence of cancer has declined slightly over the past decade.</p><p>However, traditional therapies are only effective for some early malignant tumors [<xref rid="B27-ijms-22-09118" ref-type="bibr">27</xref>,<xref rid="B28-ijms-22-09118" ref-type="bibr">28</xref>,<xref rid="B29-ijms-22-09118" ref-type="bibr">29</xref>], and the main reasons for eventual failure of tumor treatment are metastasis [<xref rid="B30-ijms-22-09118" ref-type="bibr">30</xref>], recurrence [<xref rid="B31-ijms-22-09118" ref-type="bibr">31</xref>], heterogeneity [<xref rid="B32-ijms-22-09118" ref-type="bibr">32</xref>], chemotherapy resistance [<xref rid="B33-ijms-22-09118" ref-type="bibr">33</xref>], and avoidance of immune surveillance [<xref rid="B34-ijms-22-09118" ref-type="bibr">34</xref>]. Chemotherapy is mainly achieved by using chemotherapeutic drugs to kill cancer cells [<xref rid="B35-ijms-22-09118" ref-type="bibr">35</xref>,<xref rid="B36-ijms-22-09118" ref-type="bibr">36</xref>]. As a means of systemic treatment, the drug often circulates throughout most of the organs and tissues of the body with the blood, which can cause damage to other healthy tissues and organs [<xref rid="B37-ijms-22-09118" ref-type="bibr">37</xref>,<xref rid="B38-ijms-22-09118" ref-type="bibr">38</xref>]. However, chemotherapy has a reliable effect on some tumors that tend to spread throughout the body and on metastatic tumors [<xref rid="B39-ijms-22-09118" ref-type="bibr">39</xref>,<xref rid="B40-ijms-22-09118" ref-type="bibr">40</xref>,<xref rid="B41-ijms-22-09118" ref-type="bibr">41</xref>]. The classic chemotherapeutic drugs (doxorubicin (Dox) [<xref rid="B42-ijms-22-09118" ref-type="bibr">42</xref>], vemurafenib [<xref rid="B43-ijms-22-09118" ref-type="bibr">43</xref>], and paclitaxel (PTX) [<xref rid="B44-ijms-22-09118" ref-type="bibr">44</xref>]) are still the mainstay of current treatment, but they are limited by narrow treatment indicators, significant toxicity, and frequent acquired drug resistance. Traditional chemotherapy interferes with DNA synthesis and mitosis, leading to the death of fast-growing and dividing cancer cells [<xref rid="B16-ijms-22-09118" ref-type="bibr">16</xref>,<xref rid="B45-ijms-22-09118" ref-type="bibr">45</xref>,<xref rid="B46-ijms-22-09118" ref-type="bibr">46</xref>]; however, these drugs are non-selective and can damage healthy normal tissues, causing serious complications and undesirable side effects, such as loss of appetite and nausea. In fact, the severe adverse effects of chemotherapy drugs on healthy tissues and organs are the main reason for the high mortality of cancer patients.</p><p>Further research into the pathogenesis of cancer has led to new treatment options, including targeted therapy [<xref rid="B47-ijms-22-09118" ref-type="bibr">47</xref>,<xref rid="B48-ijms-22-09118" ref-type="bibr">48</xref>] and immunotherapy [<xref rid="B49-ijms-22-09118" ref-type="bibr">49</xref>,<xref rid="B50-ijms-22-09118" ref-type="bibr">50</xref>]. Targeted chemotherapy mainly uses molecular targeted drugs to block specific molecules and metabolic pathways in tumor cell growth and proliferation. Compared to other types of cancer treatments, targeted therapy can achieve the greatest therapeutic effect and lowest toxicity. In particular, the more targeted the drug, the lower the possibility of drug resistance. The clinical success of immunotherapy has revolutionized the treatment of a variety of advanced malignant tumors [<xref rid="B51-ijms-22-09118" ref-type="bibr">51</xref>,<xref rid="B52-ijms-22-09118" ref-type="bibr">52</xref>]. However, most patients do not benefit from existing immunotherapies, and many patients experience immune-related adverse events [<xref rid="B53-ijms-22-09118" ref-type="bibr">53</xref>]. It is generally believed that the development of new anticancer drugs has greatly improved the survival and quality of life of cancer patients. However, in many cases, these drugs show a good response during initial treatment, but later on in the treatment, the efficacy of the drugs decreases and can lead to cancer recurrence. This phenomenon is called acquired drug resistance and is a major problem in the treatment of cancer [<xref rid="B54-ijms-22-09118" ref-type="bibr">54</xref>,<xref rid="B55-ijms-22-09118" ref-type="bibr">55</xref>,<xref rid="B56-ijms-22-09118" ref-type="bibr">56</xref>]. The formation of drug resistance is mainly due to a kind of internal resistance that develops within tumor cells [<xref rid="B57-ijms-22-09118" ref-type="bibr">57</xref>,<xref rid="B58-ijms-22-09118" ref-type="bibr">58</xref>,<xref rid="B59-ijms-22-09118" ref-type="bibr">59</xref>]. A specific cell membrane transporter changes the drug transport and pumps the drug out of tumor cells [<xref rid="B60-ijms-22-09118" ref-type="bibr">60</xref>]. In addition, the gradual acquisition of specific heredity and epigenetics in cancer cells during the treatment process greatly contributes to acquired drug resistance [<xref rid="B54-ijms-22-09118" ref-type="bibr">54</xref>]. Drug resistance is defined as a decline in the efficacy and potency of a drug in order to limit treatment, ultimately leading to failure in the treatment of the disease [<xref rid="B61-ijms-22-09118" ref-type="bibr">61</xref>]. Tumors such as kidney cancer [<xref rid="B62-ijms-22-09118" ref-type="bibr">62</xref>], hepatocellular carcinoma [<xref rid="B63-ijms-22-09118" ref-type="bibr">63</xref>], and malignant melanoma [<xref rid="B64-ijms-22-09118" ref-type="bibr">64</xref>] often respond well to chemotherapy in the early stage, but become unresponsive in later stages of treatment due to the development of acquired drug resistance.</p><p>In order to solve these problems, we urgently need to develop new treatment methods to help improve clinical efficacy. The emergence of nanotechnology has had a profound impact on the clinical treatment of tumors, which has promoted the rapid development of targeted therapy [<xref rid="B64-ijms-22-09118" ref-type="bibr">64</xref>,<xref rid="B65-ijms-22-09118" ref-type="bibr">65</xref>,<xref rid="B66-ijms-22-09118" ref-type="bibr">66</xref>], combined drug therapy [<xref rid="B67-ijms-22-09118" ref-type="bibr">67</xref>,<xref rid="B68-ijms-22-09118" ref-type="bibr">68</xref>], and early tumor diagnosis [<xref rid="B69-ijms-22-09118" ref-type="bibr">69</xref>]. Among them, NDDSs have become a research hotspot at the interface between nanotechnology and biomedicine, because of their efficient loading, targeted delivery, controlled release, and other functions for drugs, and show promise in biomedical applications [<xref rid="B70-ijms-22-09118" ref-type="bibr">70</xref>,<xref rid="B71-ijms-22-09118" ref-type="bibr">71</xref>]. For example, silicon-based nanomaterials [<xref rid="B72-ijms-22-09118" ref-type="bibr">72</xref>], polymers [<xref rid="B73-ijms-22-09118" ref-type="bibr">73</xref>], liposomes, and metal NPs [<xref rid="B74-ijms-22-09118" ref-type="bibr">74</xref>] are designed to deliver anticancer drugs to tumor tissues. In various NDDSs, polymer-functionalized nanomaterials have attracted widespread attention as excellent candidate materials for therapeutic drug delivery, especially based on their multivalent binding ability and ideal biocompatibility [<xref rid="B75-ijms-22-09118" ref-type="bibr">75</xref>,<xref rid="B76-ijms-22-09118" ref-type="bibr">76</xref>]. In this paper, we discuss various types of polymer NPs and focus on their applications in traditional chemotherapy, immunotherapy, gene therapy, and combination therapy.</p></sec><sec id="sec2-ijms-22-09118"><title>2. Nanocarriers</title><sec id="sec2dot1-ijms-22-09118"><title>2.1. Physical and Chemical Properties of Nanocarriers</title><p>In recent years, NP delivery systems as drug delivery carriers have aroused extensive research interest in the field of cancer precision medicine. NPs are particle dispersions or solid particles with a particle size in the range of 10&#x02013;1000 nm [<xref rid="B77-ijms-22-09118" ref-type="bibr">77</xref>]. Depending on the material, the NPs include lipids (liposomes) [<xref rid="B78-ijms-22-09118" ref-type="bibr">78</xref>], polymers (artificial synthetic polymer NPs and natural polymer NPs) [<xref rid="B79-ijms-22-09118" ref-type="bibr">79</xref>], inorganic NPs (silicon NPs) [<xref rid="B80-ijms-22-09118" ref-type="bibr">80</xref>], organic compounds (carbon nanotubes) [<xref rid="B81-ijms-22-09118" ref-type="bibr">81</xref>], and metal NPs (gold NPs, silver NPs, magnetic NPs, etc.) [<xref rid="B82-ijms-22-09118" ref-type="bibr">82</xref>]. Most studies have suggested that the NP delivery systems described above can be used to alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug molecules [<xref rid="B83-ijms-22-09118" ref-type="bibr">83</xref>,<xref rid="B84-ijms-22-09118" ref-type="bibr">84</xref>,<xref rid="B85-ijms-22-09118" ref-type="bibr">85</xref>]. The main reason is that NP delivery systems prolong the half-life of the drug in vivo, limit the entry of the drug into normal histiocytes, and regulate the release of the drug in the target organ tissue at a controllable and continuous rate. As ideal nanodrug delivery systems, in addition to being able to specifically target drug delivery to tumor tissue, NPs must also have a long circulatory function that is not easily recognized by the phagocytic cells of the reticuloendothelial system. The physical and chemical properties of NPs consist primarily of the following: Size, surface charge, shape, composition, and modification of surface groups [<xref rid="B86-ijms-22-09118" ref-type="bibr">86</xref>,<xref rid="B87-ijms-22-09118" ref-type="bibr">87</xref>].</p><p>The particle size and particle size distribution of NPs are two of the most important characteristics of drug delivery systems [<xref rid="B88-ijms-22-09118" ref-type="bibr">88</xref>]. They determine the distribution, half-life, toxicity, and targeting ability of NP systems in vivo [<xref rid="B89-ijms-22-09118" ref-type="bibr">89</xref>]. In addition, they affect the drug loading, release, and stability of NPs. The release of a drug is mainly affected by the size of the particle. Smaller particles have a larger surface area, so most of the drug contained in the carrier attaches to or near the surface of the particle, resulting in rapid drug release [<xref rid="B90-ijms-22-09118" ref-type="bibr">90</xref>]. It is known that the clearance rate of very small NPs can be faster, and most of these NPs end up in the liver and spleen; hence, the usage of these targeted NPs is impractical and ineffective. On the other hand, micro-carriers are too large to be administered through small capillaries. Therefore, choosing the right material and particle size is another important aspect in the selection of proper targeting NPs to treat cancer. Nowadays, researchers can rely on the preparation process to adjust the size of NPs according to actual needs [<xref rid="B91-ijms-22-09118" ref-type="bibr">91</xref>].</p></sec><sec id="sec2dot2-ijms-22-09118"><title>2.2. Challenges and Strategies of NPs as Drug Delivery Carriers in Cancer Therapy</title><p>Nanocarriers have important advantages, including adjustable physical and chemical properties, ease of production, scalability, and stability during storage [<xref rid="B92-ijms-22-09118" ref-type="bibr">92</xref>]. Compared with other delivery vehicles, these are the basic factors for expanding clinical applicability. The fundamental challenge of using NPs for successful gene therapy lies in biological barriers, targeted therapy, and safety [<xref rid="B93-ijms-22-09118" ref-type="bibr">93</xref>]. Understanding these obstacles in cancer gene therapy in detail and developing methods to bypass them are critical to realizing NPs&#x02019; ultimate potential.</p><sec id="sec2dot2dot1-ijms-22-09118"><title>2.2.1. Biodistribution and Barrier Properties</title><p>The biodistribution of NPs includes the two interrelated challenges of nano-drug particles gathering in unwanted locations as well as targeting target locations, and their guidance or misdirection by barrier properties [<xref rid="B94-ijms-22-09118" ref-type="bibr">94</xref>]. The biodistribution and final particle activity largely depend on the protein corona that forms initially upon contact of the nanomaterial with the body&#x02019;s various biological components [<xref rid="B95-ijms-22-09118" ref-type="bibr">95</xref>]. Change in the protein corona relies heavily on the physicochemical properties of the polymer NPs and circulation time. In addition, barrier properties to drug delivery can prevent the successful accumulation of nano-therapeutic drugs at the disease site, limiting effective responses to disease processes from cancer to inflammation. These obstacles include arrangement and subsequent isolation of the mononuclear phagocytic system (MPS), nonspecific distribution, blood/vascular flow restriction, pressure gradients, cellular internalization, escape from endocrine and lysozyme chambers, and drug excretion pumps [<xref rid="B96-ijms-22-09118" ref-type="bibr">96</xref>]. Although a large number of research efforts are aimed at incorporating multiple functions and functions into the overall nanoparticle design, many of these strategies have failed to adequately address these obstacles [<xref rid="B97-ijms-22-09118" ref-type="bibr">97</xref>]. Traditional NPs need to be reimagined to successfully resolve these obstacles that hinder drug delivery. Unless nanodrugs are designed with consideration of most (if not all) biological barriers encountered where NPs can escape after entering the body, these obstacles will continue to limit their clinical application in tumor treatment.</p><p>In order to overcome the challenges of mass transport across barrier properties and biodistribution, receptor targeting ligands and peptides have been used as mechanisms for the direct transport of therapeutic NPs, as well as cell-mediated drug transport. In recent years, the surface characteristics of NPs have been identified as important factors in determining their lifetime and fate, and are related to their capture by macrophages during the cycling process [<xref rid="B98-ijms-22-09118" ref-type="bibr">98</xref>,<xref rid="B99-ijms-22-09118" ref-type="bibr">99</xref>]. Ideally, NPs with a hydrophilic surface can more easily escape capture by macrophages. At present, the surface of NPs is generally modified, for example by coating the surface of NPs with hydrophilic polymers (such as poly(ethylene glycol) (PEG)) to prevent the formation of a proteins corona in order to extend the circulation period of NPs in vivo [<xref rid="B100-ijms-22-09118" ref-type="bibr">100</xref>,<xref rid="B101-ijms-22-09118" ref-type="bibr">101</xref>,<xref rid="B102-ijms-22-09118" ref-type="bibr">102</xref>]. Gao et al. found that the larger the PEG modification on the surface of gold NPs, the smaller the particle size and the lower the plasma protein adsorption capacity, which inhibited the formation of a &#x0201c;proteins corona&#x0201d; and enhanced targeting ability mediated by the arginine&#x02013;glycine&#x02013;aspartate (RGD) peptide [<xref rid="B103-ijms-22-09118" ref-type="bibr">103</xref>]. The strategy of functionalizing NPs with PEG or PEGylation is mainly derived from the observation that the circulatory life of NPs is low after intravascular administration [<xref rid="B104-ijms-22-09118" ref-type="bibr">104</xref>]. PEGylation involves grafting PEG onto the surface of NPs, where ethylene glycol units are closely associated with water molecules to form a moisturizing layer [<xref rid="B105-ijms-22-09118" ref-type="bibr">105</xref>]. This moisturizing layer in turn hinders protein adsorption and subsequent removal of MPS. In addition, researchers have recently developed a biomimetic particle coating composed of cell membranes separated from corresponding cells (red blood cells, white blood cells and tumor cells, etc.) [<xref rid="B65-ijms-22-09118" ref-type="bibr">65</xref>,<xref rid="B106-ijms-22-09118" ref-type="bibr">106</xref>,<xref rid="B107-ijms-22-09118" ref-type="bibr">107</xref>], which enhanced the immune escape of NPs and extended the lifetime of drugs in the body. When the cell membrane surface was functionalized, amount of protein (IgG and albumin) adsorbed on the particle surface was reduced by over 10-fold [<xref rid="B108-ijms-22-09118" ref-type="bibr">108</xref>]. Therefore, this biomimetic coating strategy significantly reduced the uptake of particles by macrophages, especially when the coating originated from the same donor species. Consistently, a low accumulated degree of functionalized particles in the liver has been observed when testing such a platform in a mouse model by systemic administration [<xref rid="B109-ijms-22-09118" ref-type="bibr">109</xref>].</p></sec><sec id="sec2dot2dot2-ijms-22-09118"><title>2.2.2. Tumor Targeting</title><p>Heterogeneity, high metastasis, and invasiveness within the tumor, as well as the lack of clear tumor surface markers, further hinder the development of efficient targeted drug/gene delivery [<xref rid="B110-ijms-22-09118" ref-type="bibr">110</xref>]. At present, there are many options for achieving tumor-targeted gene delivery. For example, our previous work mainly focused on passive targeting through the enhanced permeability and retention (EPR) effect or through cancer cell-specific ligands (such as antibodies, peptides, and surface mountants) [<xref rid="B111-ijms-22-09118" ref-type="bibr">111</xref>,<xref rid="B112-ijms-22-09118" ref-type="bibr">112</xref>]. Active targeting enhances the targeting ability of NPs to maximize tumor distribution and deep tissue penetration. In recent years, targeting the tumor microenvironment has become a promising strategy to overcome tumor resistance, prevent metastasis, and improve the efficacy of gene therapy [<xref rid="B113-ijms-22-09118" ref-type="bibr">113</xref>]. NPs have been designed to be sensitive to low pH and high metalloproteinase-2 levels in the tumor microenvironment and locally regulate angiogenesis and hypoxia. Recently, Wang et al. have shown that pH-sensitive drug delivery systems can deliver and release drugs within cancer cells and/or in a more acidic microenvironment inside cancer cells [<xref rid="B114-ijms-22-09118" ref-type="bibr">114</xref>]. Collectively, given the heterogeneity of tumors, rational design and evaluation of NPs are necessary.</p></sec><sec id="sec2dot2dot3-ijms-22-09118"><title>2.2.3. Safety of Nanocarriers</title><p>Safety is another important concern for translational medicine. The main goal of designing NPs as drug delivery systems is to control the particle size, surface properties, and release of pharmaceutically active substances, so that the drug can be accurately delivered to the pathological site under the best time and dosage regimen for treatment. Liposomes have become one of the first nanocarriers used in clinical treatments due to their unique advantages [<xref rid="B115-ijms-22-09118" ref-type="bibr">115</xref>]. Liposomes can effectively protect the drug from degradation, target the site of action, and reduce the toxicity or side effects, but their application is limited by inherent problems such as low encapsulation efficiency, rapid seepage of water-soluble drug during in vivo circulation, and poor stability [<xref rid="B116-ijms-22-09118" ref-type="bibr">116</xref>]. Researchers have found that polymer NPs are more likely than liposomes to help stabilize drugs (proteins and genes) and have useful controlled release properties [<xref rid="B66-ijms-22-09118" ref-type="bibr">66</xref>,<xref rid="B117-ijms-22-09118" ref-type="bibr">117</xref>,<xref rid="B118-ijms-22-09118" ref-type="bibr">118</xref>]. In addition, the potential toxicity and safety issues of most nanomaterials are the main factors limiting their clinical applications [<xref rid="B119-ijms-22-09118" ref-type="bibr">119</xref>]. In vivo, these materials may cause immune responses and cytotoxicity, and may have the ability to clear in the internal organs [<xref rid="B120-ijms-22-09118" ref-type="bibr">120</xref>]. At the same time, nanomaterials are often endowed with the ability to cross various barriers and interact with different cellular components such as proteins, lipids, and genetic materials. Therefore, a comprehensive assessment of the safety of nanomaterials will help their application in the clinical treatment of tumors [<xref rid="B121-ijms-22-09118" ref-type="bibr">121</xref>]. Polymer NPs exhibit properties such as easy degradation, low immunogenicity, and non-toxicity, which have attracted much attention from researchers [<xref rid="B122-ijms-22-09118" ref-type="bibr">122</xref>]. For example, the biodegradable synthetic polymers commonly used in drug delivery applications, namely PLA and PLGA, have been approved by the US Food and Drug Administration (FDA) [<xref rid="B123-ijms-22-09118" ref-type="bibr">123</xref>,<xref rid="B124-ijms-22-09118" ref-type="bibr">124</xref>] because of their confirmed safety and biocompatibility and low levels of immunogenicity and toxicity, and their degraded oligomers in the body are easily excreted through a common metabolic pathway [<xref rid="B125-ijms-22-09118" ref-type="bibr">125</xref>].</p></sec></sec><sec id="sec2dot3-ijms-22-09118"><title>2.3. Polymer NPs</title><p>Further research on polymer NPs is of great significance to researchers in the fields of science and medicine. Polymer NPs play a central role in a variety of applications, such as drug delivery, medical imaging, and the early detection of disease [<xref rid="B126-ijms-22-09118" ref-type="bibr">126</xref>,<xref rid="B127-ijms-22-09118" ref-type="bibr">127</xref>,<xref rid="B128-ijms-22-09118" ref-type="bibr">128</xref>]. Polymer NPs are particles obtained from natural (chitosan [<xref rid="B129-ijms-22-09118" ref-type="bibr">129</xref>], sodium alginate [<xref rid="B111-ijms-22-09118" ref-type="bibr">111</xref>] and cyclodextrin [<xref rid="B130-ijms-22-09118" ref-type="bibr">130</xref>], etc.), semi-synthetic or synthetic polymers (poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) [<xref rid="B131-ijms-22-09118" ref-type="bibr">131</xref>], <italic>N</italic>-(2-hydroxypropyl)methacrylamide (HPMA) [<xref rid="B132-ijms-22-09118" ref-type="bibr">132</xref>] and poly(acrylamide) (PAM) [<xref rid="B133-ijms-22-09118" ref-type="bibr">133</xref>]). Polymer nanosystems are produced by the polymerization of many monomer units. Under certain conditions, they can be organized and self-assembled to the size of 10&#x02013;200 nm. Polymer nanocarriers are generally divided into five types, namely micelles, nanogels, capsules, dendrimers, and mixed NPs with porous cores [<xref rid="B134-ijms-22-09118" ref-type="bibr">134</xref>]. Polymer NPs have a relatively large surface area, which facilitates the surface modification of functional groups and increases the specific distribution of drugs in the body [<xref rid="B135-ijms-22-09118" ref-type="bibr">135</xref>]. Moreover, the controlled release properties of polymer NPs and their protective effects on compounds make these NDDSs very advantageous, especially in the field of drug delivery applications. Currently, various polymers have been used in NP drug delivery research to increase the therapeutic benefits while minimizing side effects (<xref ref-type="fig" rid="ijms-22-09118-f001">Figure 1</xref>). Overall, the advantages of polymer NPs as carriers include controlled release, protection, and specific targeting ability of drug molecules.</p></sec></sec><sec id="sec3-ijms-22-09118"><title>3. Application of Polymer Nanocarriers in Tumor Targeted Therapy</title><sec id="sec3dot1-ijms-22-09118"><title>3.1. Chemotherapy Based on Polymer Nanocarriers</title><p>Chemotherapy is the most common treatment for cancer [<xref rid="B14-ijms-22-09118" ref-type="bibr">14</xref>]. As is well-established, chemotherapeutic drugs can be divided into alkylating agents (nimustine, cyclophosphamide, glycosyl mustard, etc.) [<xref rid="B138-ijms-22-09118" ref-type="bibr">138</xref>], antimetabolites (deoxyfluoroguanosine, amcitabine, 5-fluorouracil, etc.) [<xref rid="B139-ijms-22-09118" ref-type="bibr">139</xref>], antitumor antibiotics (actinomycin D, Dox, and pelomycin) [<xref rid="B140-ijms-22-09118" ref-type="bibr">140</xref>], antitumor plant and animal ingredients (hydroxycamptothecin, PTX, etc.) [<xref rid="B141-ijms-22-09118" ref-type="bibr">141</xref>], antitumor hormones (atamitan, anastrozole, and nolvadex, etc.) [<xref rid="B142-ijms-22-09118" ref-type="bibr">142</xref>], etc. Unfortunately, the current clinical application of antitumor chemotherapeutic drugs has led to unforeseen toxicity and side effects, thus limiting the drug dosage and use. When they kill tumor cells, they also damage normal tissue cells [<xref rid="B143-ijms-22-09118" ref-type="bibr">143</xref>]. Among them, the destruction of the body&#x02019;s immune system caused by the killing of lymphoid tissue cells further aggravates the development of cancer. In addition, due to its toxic and side effects, chemotherapy sometimes has complications such as infection and bleeding. To solve these problems, polymer NPs, as chemotherapeutic drug delivery systems, not only have high drug loading capacities but also can target the delivery of drugs to cancer tissues and control the release of drugs [<xref rid="B144-ijms-22-09118" ref-type="bibr">144</xref>]. Polymer NDDSs can improve drug hydrophilicity and encapsulation efficiency, thereby protecting fragile molecules from early degradation/metabolism and prolonging the half-life of the drug during the metabolic cycle. As shown in <xref rid="ijms-22-09118-t001" ref-type="table">Table 1</xref>, these drug delivery systems can specifically deliver chemotherapeutic drugs to tumor sites and reduce toxicity and side effects.</p><p>Fang et al. found that Dox-loaded dextran-based nanocarriers are an effective drug delivery system for the treatment of malignant lymphoma with reduced cardiotoxicity [<xref rid="B158-ijms-22-09118" ref-type="bibr">158</xref>]. First, dextran reacts with the monomer methyl-acrylate under the catalysis of cerium ammonium nitrate, and then the crosslinking agent diallyl-disulfide is added to form a new type of nanocarrier [<xref rid="B159-ijms-22-09118" ref-type="bibr">159</xref>]. Finally, Dox is covalently bonded to the nanocarrier through a hydrazone bond. This novel drug delivery system not only has a high drug loading capacity and pH sensitivity, but can also reduce cell resistance. The emergence of multidrug resistance in cancer treatment is a huge challenge that limits drug efficacy, thus leading to the failure of many chemotherapy drugs in clinical treatment. As far as polymer NPs are concerned, Cuvier et al. [<xref rid="B160-ijms-22-09118" ref-type="bibr">160</xref>], Nemati et al. [<xref rid="B161-ijms-22-09118" ref-type="bibr">161</xref>], and Verdi&#x000e8;re et al. [<xref rid="B162-ijms-22-09118" ref-type="bibr">162</xref>]. showed that Dox-loaded polyalkylcyanoacrylate NPs (PACA NPs) can overcome multidrug resistance. In 1997, Verdi&#x000e8;re et al. used Dox-loaded PACA NPs to overcome multidrug resistance in vitro. They found that the main reason for PACA NPs&#x02019; ability to reverse multidrug resistance was that the NPs adsorbed onto the surface of tumor cells and then released their coated drugs, thereby forming a local highly concentrated gradient drug concentration around the tumor cells. At the same time, the degradation and release of polycyanoacrylic acid and other compounds by NPs may have interacted with Dox, which may have promoted the accumulation of Dox in tumor cells by overcoming the transmembrane potential. Moreover, Vlerken et al. found that polymer NPs can be used to modulate intracellular ceramide to overcome multidrug resistance in cancer [<xref rid="B163-ijms-22-09118" ref-type="bibr">163</xref>]. In 2015, Yuan et al. proposed self-assembled nanodrugs in cells as a new strategy for overcoming multidrug resistance [<xref rid="B164-ijms-22-09118" ref-type="bibr">164</xref>]. They designed a taxol derivative (Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol)) through a biocompatible condensation reaction. The results showed that the lethality of CBT-Taxol to taxol-resistant HCT 116 cancer cells was significantly higher than that of free taxol. Furthermore, CBT-Taxol had a more lasting effect on tubulin condensation, possibly due to its ability to slowly release taxol in tumor cells. Therefore, the construction of intracellular self-assembled nanodrugs may be a new and optimal strategy to overcome drug resistance. At present, many NP-based drug delivery systems have been developed to overcome drug resistance by increasing cell uptake and rapid drug release to increase the intracellular drug concentration. Wang et al. designed a polypeptide dendritic copolymer NP to encapsulate and target Dox and to overcome multidrug resistance by regulating the lysosomal pathway of breast cancer cell apoptosis [<xref rid="B165-ijms-22-09118" ref-type="bibr">165</xref>]. Mu et al. developed self-assembled NPs based on chitosan grafted with cholesterol hemisuccinate to enhance the absorption of docetaxel by multidrug-resistant cancer cells [<xref rid="B166-ijms-22-09118" ref-type="bibr">166</xref>]. In 2021, a novel type of folic acid-modified chitosan-silica NPs were used to co-deliver PTX and P-shRNA [<xref rid="B167-ijms-22-09118" ref-type="bibr">167</xref>]. These NPs could effectively protect P-shRNA from degradation and exhibited pH-responsive drug release behavior. As a targeting ligand, folic acid could improve the uptake efficiency of NPs by multidrug-resistant breast cancer cells. In addition, these NPs showed excellent P-shRNA release ability in cells, and effectively silenced the expression of the target gene P-gp, thereby reducing the multidrug resistance to the PTX. Therefore, polymer nanocarriers can help to reduce the emergence of multidrug resistance for chemotherapeutic drugs in clinical treatment, can greatly improve the clinical efficacy of chemotherapeutics, and can bring about a new dawn for patients.</p></sec><sec id="sec3dot2-ijms-22-09118"><title>3.2. Gene Therapy Based on Polymer Nanocarriers</title><p>Gene therapy is a technology that treats or cures diseases by modifying a person&#x02019;s genes. Gene therapy can work through the following mechanisms: (i) replacing disease-causing genes with healthy genes; (ii) inactivating disease-causing genes; (iii) introducing new or modified genes into the body to help treat diseases [<xref rid="B168-ijms-22-09118" ref-type="bibr">168</xref>,<xref rid="B169-ijms-22-09118" ref-type="bibr">169</xref>]. There are many types of gene therapy products, including plasmid DNA, viral vectors, bacterial vectors, gene editing technology, and patient-derived cell gene therapy products [<xref rid="B170-ijms-22-09118" ref-type="bibr">170</xref>]. Among them, gene editing refers to the process of making tiny, controllable changes to the DNA of organisms, mainly using the CRISPR/Cas9 method [<xref rid="B171-ijms-22-09118" ref-type="bibr">171</xref>]. Although advances have been made in various nucleotide-based therapies, the low efficiency of targeted tissue or cell delivery has limited the clinical application of gene therapy [<xref rid="B172-ijms-22-09118" ref-type="bibr">172</xref>]. In the blood circulation, small nucleic acid molecules are easily degraded by enzymes in plasma. In vivo fluids, the phosphate bonds of nucleic acids, are gradually broken by exonuclease and then cleared by glomerular filtration, and are excreted from the body with urine. Gao et al. have also found that, in the extracellular environment, the half-life of naked small nucleic acid molecules ranges from a few minutes to a few hours, so they cannot be enriched in large amounts to target cells, thereby reducing the bioavailability of the drug and leading to poor efficacy [<xref rid="B173-ijms-22-09118" ref-type="bibr">173</xref>]. Based on these problems, we urgently need a new delivery vehicle to enhance the therapeutic response of gene agents (siRNA [<xref rid="B174-ijms-22-09118" ref-type="bibr">174</xref>], miRNA [<xref rid="B175-ijms-22-09118" ref-type="bibr">175</xref>], mRNA [<xref rid="B176-ijms-22-09118" ref-type="bibr">176</xref>], and CRISPR/Cas9 [<xref rid="B177-ijms-22-09118" ref-type="bibr">177</xref>]) in the system environment. Given the high instability of naked nucleic acid in systemic circulation, the poor permeability of biofilm, and the ease of missing the target, along with other shortcomings, the design of an appropriate carrier must have the following characteristics: (i) a high encapsulation rate for nucleic acid drugs; (ii) the ability to protect the stable structure of nucleic acid molecules; (iii) accurate delivery of nucleic acid drugs to target tissues and cells.</p><p>In recent decades, nanotechnology has made major breakthroughs in the development of safe and efficient gene vectors (<xref rid="ijms-22-09118-t002" ref-type="table">Table 2</xref>). Compared to viral vectors, nanocarriers not only have good biosafety but can also deliver gene agents to target cells with high efficiency [<xref rid="B178-ijms-22-09118" ref-type="bibr">178</xref>]. In addition, NDDSs can maintain their functions while improving the bioavailability of drugs and reducing off-target effects. Among existing nanocarriers, polymer nanocarriers are attracting a great deal of attention due to their non-toxicity, low immunogenicity, and high biocompatibility. RNA interference (RNAi) is a promising technique for regulating tumor genes in cancer therapy [<xref rid="B179-ijms-22-09118" ref-type="bibr">179</xref>]. Effective cancer treatment using RNAi requires efficient delivery of siRNA and silencing of target genes in cancer cells. NDDSs are a relatively convenient way to deliver therapeutic siRNA to solid tumors, including tumor metastasis. However, there are multiple obstacles to delivering therapeutic siRNA to the cytoplasm of cancer cells. To overcome the challenges of current siRNA delivery vehicles, researchers have designed many interesting and increasingly complete drug delivery systems. Johan et al. prepared poly(&#x003b2;-amino ester)s (PBAE) through a two-step method and designed a bioreducible PBAE&#x02013;siRNA NP for the systematic delivery of siRNA in vivo to brain tumors [<xref rid="B180-ijms-22-09118" ref-type="bibr">180</xref>]. NPs based on PBAE have high in vitro permeability, and the positively charged surface improves siRNA loading efficiency and can remain stable in the presence of serum proteins. In addition, the diameter of PBAE NPs is approximately 57 nm, small enough to cross the blood&#x02013;brain barrier (BBB) to reach the glioma site and specifically inhibit the expression of target genes. Li et al. reported a dual supramolecular nanocomposite composed of &#x003b1;-cyclodextrin-modified hyaluronic acid and an azobenzene-modified diphenylalanine derivative with a positively charged imidazole group [<xref rid="B181-ijms-22-09118" ref-type="bibr">181</xref>]. Such nanocarriers can bind to siRNA through electrostatic interactions, and effectively deliver them to cancer cells in order to inhibit their growth. In addition, the azobenzene double bonds of NDDs are isomerized under ultraviolet radiation (365 nm), resulting in the disintegration of the NPs to release siRNA, while showing good cytotoxicity toward cancer cells. Li et al. believed that a new drug delivery system was expected to overcome the shortcomings of the high-density positive charges of gene transfection reagents, damaging the membranes and cells of normal cells, thereby providing a promising method for gene delivery. Ashley et al. have shown that most NPs are recognized and eliminated by the immune system, limiting the bioavailability of gene agents [<xref rid="B182-ijms-22-09118" ref-type="bibr">182</xref>]. Biomimetic NPs modified with active cell membranes are now one of the most attractive nanostructures. The invisibility of cell membranes allows biomimetic NPs to be altered and functionalized with self-awareness and targeting capabilities to dilate blood circulation and avoid immune capture. Chen et al. designed a cancer cell membrane cloaking NP for the targeted co-delivery of Dox and programmed death-ligand 1 (PD-L1) siRNA [<xref rid="B183-ijms-22-09118" ref-type="bibr">183</xref>]. Cancer cell membrane-covered polymer NPs show good internalization of self-recognition, which can effectively camouflage the nanocarrier while also having multiple membrane antigens and surface functionalization.</p><p>Therefore, the combination of gene therapy and a nanocarrier-mediated drug delivery system holds important prospects for future cancer treatment. Furthermore, gene therapy offers a promising strategy for cancer treatment by specifically targeting oncogenes. More interestingly, the above strategies can also be combined with NP-mediated imaging methods to safely track and identify the biodistribution of nanomedicines. At the same time, the emergence of polymer nanocarriers has improved the serious challenges of toxicity and immunogenicity posed by other types of nanocarriers, and has broadened the clinical application of nanocarriers in cancer therapy.</p></sec><sec id="sec3dot3-ijms-22-09118"><title>3.3. Immunotherapy Based on Polymer Nanocarriers</title><p>In the past decade, cancer immunotherapy has received great attention. Cancer immunotherapy mainly uses immune checkpoint inhibitors, agonists, antigens, and chimeric antigen receptor T cells to activate the patient&#x02019;s innate and adaptive immune system to combat tumor cells [<xref rid="B189-ijms-22-09118" ref-type="bibr">189</xref>,<xref rid="B190-ijms-22-09118" ref-type="bibr">190</xref>]. Unlike other oncologic therapies (such as chemotherapy, radiotherapy, and surgery), immunotherapy aims to restore the antitumor activity of the immune system and use the patient&#x02019;s own immune system to attack abnormal cells, thereby improving efficacy and reducing missed targets in the treatment of advanced malignant tumors [<xref rid="B191-ijms-22-09118" ref-type="bibr">191</xref>]. In recent years, cancer immunotherapy has achieved some significant clinical successes, including cancer vaccines obtaining FDA approval, and immune checkpoint blockade (ICB) [<xref rid="B192-ijms-22-09118" ref-type="bibr">192</xref>], adoptive cell transfer (ACT) [<xref rid="B193-ijms-22-09118" ref-type="bibr">193</xref>], monoclonal antibody (mAbs) therapy [<xref rid="B194-ijms-22-09118" ref-type="bibr">194</xref>], and chimeric antigen receptor (CAR) T cell therapy with programmed cell death 1 (PD-1) [<xref rid="B195-ijms-22-09118" ref-type="bibr">195</xref>] or its ligand (PD-L1) [<xref rid="B196-ijms-22-09118" ref-type="bibr">196</xref>] as immune checkpoint inhibitors have shown promise. However, the inherent limitations of conventional immunotherapy are the difficulty of precise dose control, insufficient tumor tissue enrichment, and partial immune response silence. This has resulted in the overall response rate of patients still being less than 30%, accompanied by immune-related adverse events (enteritis, pneumonia, hepatitis, myocarditis, and neurotoxic effects) [<xref rid="B197-ijms-22-09118" ref-type="bibr">197</xref>].</p><p>Therefore, there is an urgent need to improve current cancer immunotherapies, and Ahmed et al. found that NP-based methods can improve their ability to enhance T cell activation on tumor cells and improve their antitumor efficacy with minimal toxicity [<xref rid="B198-ijms-22-09118" ref-type="bibr">198</xref>]. Effective control of the release of immune agonists or adjuvants is an important way to avoid the attacks on normal tissues and organs caused by excessive immune activation. Interestingly, studies have found that immunomodulators are encapsulated in biodegradable polymers, such as PLGA, where they are slowly released as the polymer is degraded [<xref rid="B199-ijms-22-09118" ref-type="bibr">199</xref>]. Moreover, polymer nanomaterials have been confirmed in numerous studies to have good biocompatibility, easy degradation, and non-toxicity (<xref rid="ijms-22-09118-t003" ref-type="table">Table 3</xref>).</p><p>Nahal et al. developed an approach to protein NP (pNP) engineering based on reactive electrospraying and controlled the particle size, elasticity, and mesh size at the molecular level of the pNP by controlling the PEG/ovalbumin (OVA) ratio [<xref rid="B207-ijms-22-09118" ref-type="bibr">207</xref>]. The results showed that the OVA pNPs led to a significant increase in median survival relative to solute OVA antigens in a B16F10-OVA melanoma mouse model. In addition, Nishit and Si et al. showed that by wrapping cell membranes from different cell sources onto NPs, the active proteins on the cell membranes could endow the NPs with various required functions or adjuvant therapeutic effects, providing a way to enhance cancer immunotherapy [<xref rid="B208-ijms-22-09118" ref-type="bibr">208</xref>,<xref rid="B209-ijms-22-09118" ref-type="bibr">209</xref>]. Ochyl et al. reported a novel type of PEGylated tumor cell membrane vesicles as a new vaccine platform for tumor immunotherapy, confirmed in a mouse tumor model [<xref rid="B210-ijms-22-09118" ref-type="bibr">210</xref>]. The endogenous cell membrane obtained from cancer cells forms PEGylated NPs (PEG-NPs). PEG-NPs show good serum stability in vitro and efficient drainage through local lymph nodes upon subcutaneous administration in vivo. In tumor-bearing mice, treatment with PEG-NPs synthesized by mouse melanoma cells can cause high-efficiency antigen-specific cytotoxic CD8<sup>+</sup> T lymphocyte responses. Furthermore, Wu et al. reported a surface-layer (S-layer) protein-enhanced immunotherapy strategy based on cell membrane-coated S-CM-HPAD NPs for effective malignant tumor therapy and metastasis inhibition [<xref rid="B211-ijms-22-09118" ref-type="bibr">211</xref>]. They proposed that biomimetic S-CM-HPAD NPs have the same targeting, multi-antigen immune activation and drug delivery capabilities, while encapsulated Dox can enhance the immunotherapeutic response and inhibit the growth and metastasis of melanoma tumors by inhibiting myeloid-suppressive cells. It has also been reported that NPs (Natural killer cell NPs, NK-NPs) containing the photosensitizer 4,4&#x02032;,4&#x02033;,4&#x02034;-(porphine-5,10,15,20-tetrayl) tetrakis (benzoic acid) (TCPP) can eliminate primary tumors and inhibit distant tumors through the NK cell membrane. Deng et al. found that NK-NPs enhanced NK cell membrane immunity through immunogenic photodynamic therapy (PDT) and produced a stronger immune response for tumor-targeted cell membrane immunotherapy [<xref rid="B212-ijms-22-09118" ref-type="bibr">212</xref>]. Through proteomic analysis of the NK cell membrane, they proved that the NK cell membrane can target NK-NPs to tumors and initiate the polarization of M1 macrophages to produce cell membrane immunotherapy. Thus, polymer NPs camouflaged by cell membranes have been studied in recent years as powerful drug carriers for improved immunotherapy.</p></sec><sec id="sec3dot4-ijms-22-09118"><title>3.4. Combination Therapy Based on Polymer Nanocarriers</title><p>Cancer is a complex disease driven by multiple gene mutations, and its progression involves interaction between cancer cells and their microenvironment [<xref rid="B213-ijms-22-09118" ref-type="bibr">213</xref>]. Compared to single-agent therapy, combination chemotherapy has shown better clinical treatment effects, especially in delaying the development of cancer chemotherapy resistance [<xref rid="B214-ijms-22-09118" ref-type="bibr">214</xref>,<xref rid="B215-ijms-22-09118" ref-type="bibr">215</xref>]. Studies have found that cancer cells acquire defense mechanisms by over-expressing drug efflux pumps, increasing drug metabolism, enhancing self-repair capabilities, or expressing altered drug targets, resulting in reduced efficacy and, ultimately, failure of treatment [<xref rid="B61-ijms-22-09118" ref-type="bibr">61</xref>]. In order to solve this problem, the use of two or more drugs with different pharmacological mechanisms for combined therapy is a promising treatment strategy (<xref rid="ijms-22-09118-t004" ref-type="table">Table 4</xref>). For example, in vivo efficacy of dual-drug-loaded NPs was better than that of a single formulation of combretastatin and Dox in mice with B16/F10 melanoma or Lewis lung carcinoma-bearing mice [<xref rid="B216-ijms-22-09118" ref-type="bibr">216</xref>]. Currently, various nanodrug delivery systems, such as liposomes and polymer NPs, are used to provide multiple treatments at the same time, including chemotherapeutics, siRNA/mRNA, immunoagonists, photosensitizers, and antiangiogenic agents [<xref rid="B217-ijms-22-09118" ref-type="bibr">217</xref>]. In this regard, many polymer NPs have been widely used in the treatment of various cancers. Their advantages are mainly reflected in the prolonged drug half-life, high drug loading rate, low toxicity, controlled release, and specific enrichment. In addition, an important advantage of polymer nanocarriers is that drugs with different physical and chemical properties can be co-encapsulated in the same nanocarrier and delivered to tumor cells simultaneously to achieve combined therapy [<xref rid="B218-ijms-22-09118" ref-type="bibr">218</xref>]. In our previous research, we reported the self-assembled polymer nanocarrier-mediated co-delivery of metformin and Dox for the treatment of melanoma [<xref rid="B111-ijms-22-09118" ref-type="bibr">111</xref>]. We mainly used folic acid&#x02013;sodium alginate&#x02013;cholesteric amphoteric polymer NPs to co-deliver metformin and Dox to melanoma tissues, and to inhibit tumor progression by inducing PANoptosis (pyroptosis, apoptosis, and necroptosis) of melanoma cells (<xref ref-type="fig" rid="ijms-22-09118-f002">Figure 2</xref>). To ensure effective drug release in the target tissue in an ideal manner, several strategies have been developed involving introducing stimulus responsiveness into polymer NPs, giving them a specific ability to change their structure or chemical composition in response to slight changes in the environment, which then triggers drug release. Guo et al. designed a dual-pH responsive biopolymer&#x02013;Dox conjugate NP to encapsulate lapatinib [<xref rid="B219-ijms-22-09118" ref-type="bibr">219</xref>]. In an acidic tumor environment, the surface charge conversion of NPs can be triggered, and the uptake of drug-loaded NPs and the release of drugs can be promoted by tumor cells. This is expected to have an improved therapeutic effect on breast cancer. In addition to pH-sensitive nanocarriers, Liu and his collaborators successfully prepared and modified glutathione (GSH)-responsive Fe-DSCP NPs constructed from Fe3<sup>+</sup> and the cisplatin prodrug (DSCP) [<xref rid="B220-ijms-22-09118" ref-type="bibr">220</xref>]. This cRGD-conjugated Fe-DSCP-PEG NP (Fe-DSCP-PEG&#x02013;cRGD) can be used as a tumor-specific therapeutic drug for the combined therapy of targeted chemotherapy and chemotherapy kinetics. In addition, researchers have found that biomimetic NPs have great potential in combination therapy. Wang et al. proposed that the use of erythrocyte cell membranes to disguise NPs could efficiently deliver photosensitizers and pro-hypoxic drugs in combined tumor therapy [<xref rid="B221-ijms-22-09118" ref-type="bibr">221</xref>]. Similarly, Cong Xu et al. developed a biomimetic dual-drug delivery system (Si/PNPs@HeLa) that simultaneously targeted the delivery of PTX and siRNA by camouflaging HeLa cell membranes onto siRNA/PTX co-loaded PLGA NPs [<xref rid="B222-ijms-22-09118" ref-type="bibr">222</xref>]. In summary, we have reason to believe that combined therapy mediated by nanodrug delivery systems will bring about a new dawn for the personalized treatment of tumors.</p></sec></sec><sec><title>4. Conclusions</title><p>Recent studies on NDDSs have shown that, compared to traditional chemotherapy or immunotherapy, these systems have great advantages in targeted drug delivery. Moreover, the unique physical and chemical properties of NP drug carriers make them very suitable for tumor therapy [<xref rid="B86-ijms-22-09118" ref-type="bibr">86</xref>,<xref rid="B227-ijms-22-09118" ref-type="bibr">227</xref>]. However, despite many efforts in the development of new targeted nanocarriers (including organic polymers and mixed systems with inorganic materials such as gold, silver, and silicon oxide), only a few nanocarriers have been approved for clinical use [<xref rid="B228-ijms-22-09118" ref-type="bibr">228</xref>]. This phenomenon may be due to the lack of non-specific distribution and the accumulation of targeted NPs after administration, and concerns about their safety. In order to fully evaluate the advantages and disadvantages of NP therapy, more clinical data are needed, which also helps to optimize the development of nanomedicines. In this paper, we summarized the application of polymer nanodrug delivery systems in tumor treatment. Compared to other systems, this type of drug delivery system contains highlights such as its unique high drug loading efficiency and targeting ability. Safety issues are key to designing an optimal NDDS. We found that different polymer NPs have been proven to be safe in many studies, indicating that polymer NP carriers may be a potential ideal drug delivery carrier for the clinical treatment of tumors.</p><p>With the development of NDDSs, advances in nanophototherapy/early diagnosis technology have indicated that there is development potential for multi-functional &#x0201c;smart&#x0201d; NPs, which may help to achieve individualized cancer treatment [<xref rid="B229-ijms-22-09118" ref-type="bibr">229</xref>]. Especially in cancer treatment, early detection of growing tumor cells is crucial, and determines the success or failure of the treatment [<xref rid="B230-ijms-22-09118" ref-type="bibr">230</xref>]. Nano imaging agent-based fluorescence imaging is an easy diagnostic technique which provides high spatial and temporal resolution, excellent sensitivity and good selectivity [<xref rid="B231-ijms-22-09118" ref-type="bibr">231</xref>,<xref rid="B232-ijms-22-09118" ref-type="bibr">232</xref>]. Therefore, without the need for anatomic intervention, such as the use of an endoscope or a microfiber catheter, fluorescence imaging provides the ability to diagnose the cancer organism with high sensitivity. For the practical application of fluorescence nanotechnology (FNP) in the practice of in vivo surgery, the following requirements must be followed: (i) FNP should be demonstrated with high purity and non-toxicity to ensure safe management, (ii) the biological system should have excellent colloidal stability to avoid degradation or aggregation and to increase blood circulation time, (iii) complete removal from the biological system should be guaranteed after the imaging process is completed, and (iv) dyes containing NPs should have high stable fluorescence to ensure long-term imaging and a good signal-to-noise ratio [<xref rid="B233-ijms-22-09118" ref-type="bibr">233</xref>]. Previously, we emphasized that polymer NPs have excellent biocompatibility, low toxicity or non-toxicity, and can form long-term stable particles in the biological environment. Meanwhile, polymer NPs can be loaded with fluorescein multiple times to cause fluorescence enhancement, protect the dye in the nanoparticle core from the biological environment, and avoid unnecessary side effects, such as decreased fluorescence caused by protein interactions [<xref rid="B234-ijms-22-09118" ref-type="bibr">234</xref>,<xref rid="B235-ijms-22-09118" ref-type="bibr">235</xref>]. Continuous research on NPs in preclinical and clinical research will improve the prevention, diagnosis, and treatment of cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the members of our laboratory for their continuous support of this review.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization,. W.X. and M.S.; writing&#x02014;original draft preparation, W.X., C.L., W.Z. and S.C.; literature review, B.Z., Z.T. and W.Z.; figures preparation, W.X. and Z.T.; writing&#x02014;review and editing, all authors; supervision, M.S.; funding acquisition, W.Z., C.L. and S.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was financially supported by grants from the National Natural Science Foundation of China (grant no. 31800992 to S.C., 81800512 to W.Z., 92057112 and 31771298 to C.L.), the Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University (grant no. SKLNMZZRC202005 to C.L.), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, to C.L. and S.C.).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-22-09118"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes-Farias</surname><given-names>M.</given-names></name><name><surname>Carrasco-Pozo</surname><given-names>C.</given-names></name></person-group><article-title>The anti-cancer effect of quercetin: Molecular implications in cancer metabolism</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>3177</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20133177</pub-id></element-citation></ref><ref id="B2-ijms-22-09118"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Perez-Garc&#x000ed;a</surname><given-names>J.M.</given-names></name><name><surname>Llombart-Cussac</surname><given-names>A.</given-names></name><name><surname>Curigliano</surname><given-names>G.</given-names></name><name><surname>El Saghir</surname><given-names>N.S.</given-names></name><name><surname>Cardoso</surname><given-names>F.</given-names></name><name><surname>Barrios</surname><given-names>C.H.</given-names></name><name><surname>Wagle</surname><given-names>S.</given-names></name><name><surname>Roman</surname><given-names>J.</given-names></name><name><surname>Harbeck</surname><given-names>N.</given-names></name></person-group><article-title>Enhancing global access to cancer medicines</article-title><source>CA Cancer J. Clin.</source><year>2020</year><volume>70</volume><fpage>105</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.3322/caac.21597</pub-id><?supplied-pmid 32068901?><pub-id pub-id-type="pmid">32068901</pub-id></element-citation></ref><ref id="B3-ijms-22-09118"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>G&#x000fc;ng&#x000f6;r</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Nomograms predicting overall survival and cancer-specific survival for synchronous colorectal liver-limited metastasis</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2020</year><volume>11</volume><fpage>6213</fpage></element-citation></ref><ref id="B4-ijms-22-09118"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Mengersen</surname><given-names>K.</given-names></name><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Kimlin</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name></person-group><article-title>Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017</article-title><source>Cancer</source><year>2020</year><volume>126</volume><fpage>4220</fpage><lpage>4234</lpage><pub-id pub-id-type="doi">10.1002/cncr.33078</pub-id><pub-id pub-id-type="pmid">32648980</pub-id></element-citation></ref><ref id="B5-ijms-22-09118"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Laversanne</surname><given-names>M.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B6-ijms-22-09118"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Colombet</surname><given-names>M.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Parkin</surname><given-names>D.M.</given-names></name><name><surname>Pi&#x000f1;eros</surname><given-names>M.</given-names></name><name><surname>Znaor</surname><given-names>A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Cancer statistics for the year 2020: An overview</article-title><source>Int. J. Cancer</source><year>2021</year><volume>149</volume><fpage>778</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1002/ijc.33588</pub-id><?supplied-pmid 33818764?><pub-id pub-id-type="pmid">33818764</pub-id></element-citation></ref><ref id="B7-ijms-22-09118"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>P.K.</given-names></name><name><surname>Mathur</surname><given-names>P.</given-names></name><name><surname>Nandakumar</surname><given-names>A.</given-names></name><name><surname>Fitzmaurice</surname><given-names>C.</given-names></name><name><surname>Kumar</surname><given-names>G.A.</given-names></name><name><surname>Mehrotra</surname><given-names>R.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name><name><surname>Rath</surname><given-names>G.</given-names></name><name><surname>Gupta</surname><given-names>P.C.</given-names></name><name><surname>Swaminathan</surname><given-names>R.</given-names></name></person-group><article-title>The burden of cancers and their variations across the states of India: The Global Burden of Disease Study 1990&#x02013;2016</article-title><source>Lancet Oncol.</source><year>2018</year><volume>19</volume><fpage>1289</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30447-9</pub-id><pub-id pub-id-type="pmid">30219626</pub-id></element-citation></ref><ref id="B8-ijms-22-09118"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailar</surname><given-names>J.C.</given-names></name><name><surname>Gornik</surname><given-names>H.L.</given-names></name></person-group><article-title>Cancer undefeated</article-title><source>N. Engl J. Med.</source><year>1997</year><volume>336</volume><fpage>1569</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1056/NEJM199705293362206</pub-id><pub-id pub-id-type="pmid">9164814</pub-id></element-citation></ref><ref id="B9-ijms-22-09118"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>R.</given-names></name><name><surname>Alatise</surname><given-names>O.I.</given-names></name><name><surname>Anderson</surname><given-names>B.O.</given-names></name><name><surname>Audisio</surname><given-names>R.</given-names></name><name><surname>Autier</surname><given-names>P.</given-names></name><name><surname>Aggarwal</surname><given-names>A.</given-names></name><name><surname>Balch</surname><given-names>C.</given-names></name><name><surname>Brennan</surname><given-names>M.F.</given-names></name><name><surname>Dare</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Cruz</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer surgery: Delivering safe, affordable, and timely cancer surgery</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>1193</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00223-5</pub-id><pub-id pub-id-type="pmid">26427363</pub-id></element-citation></ref><ref id="B10-ijms-22-09118"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobel</surname><given-names>O.</given-names></name><name><surname>Hank</surname><given-names>T.</given-names></name><name><surname>Hinz</surname><given-names>U.</given-names></name><name><surname>Bergmann</surname><given-names>F.</given-names></name><name><surname>Schneider</surname><given-names>L.</given-names></name><name><surname>Springfeld</surname><given-names>C.</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>D.</given-names></name><name><surname>Schirmacher</surname><given-names>P.</given-names></name><name><surname>Hackert</surname><given-names>T.</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>M.W.</given-names></name></person-group><article-title>Pancreatic cancer surgery</article-title><source>Ann. Surg.</source><year>2017</year><volume>265</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000001731</pub-id><pub-id pub-id-type="pmid">27918310</pub-id></element-citation></ref><ref id="B11-ijms-22-09118"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudra</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>N.</given-names></name><name><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name><surname>Olsen</surname><given-names>J.R.</given-names></name><name><surname>Roach</surname><given-names>M.C.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Portelance</surname><given-names>L.</given-names></name><name><surname>Mellon</surname><given-names>E.A.</given-names></name><name><surname>Bruynzeel</surname><given-names>A.</given-names></name><name><surname>Lagerwaard</surname><given-names>F.</given-names></name></person-group><article-title>Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>2123</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1002/cam4.2100</pub-id><?supplied-pmid 30932367?><pub-id pub-id-type="pmid">30932367</pub-id></element-citation></ref><ref id="B12-ijms-22-09118"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Crevoisier</surname><given-names>R.</given-names></name><name><surname>Bayar</surname><given-names>M.A.</given-names></name><name><surname>Pommier</surname><given-names>P.</given-names></name><name><surname>Muracciole</surname><given-names>X.</given-names></name><name><surname>P&#x000ea;ne</surname><given-names>F.</given-names></name><name><surname>Dudouet</surname><given-names>P.</given-names></name><name><surname>Latorzeff</surname><given-names>I.</given-names></name><name><surname>Beckendorf</surname><given-names>V.</given-names></name><name><surname>Bachaud</surname><given-names>J.-M.</given-names></name><name><surname>Laplanche</surname><given-names>A.</given-names></name></person-group><article-title>Daily versus weekly prostate cancer image guided radiation therapy: Phase 3 multicenter randomized trial</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2018</year><volume>102</volume><fpage>1420</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.07.2006</pub-id><?supplied-pmid 30071296?><pub-id pub-id-type="pmid">30071296</pub-id></element-citation></ref><ref id="B13-ijms-22-09118"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Xun</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Su</surname><given-names>M.</given-names></name></person-group><article-title>Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-ray radiation therapy of breast cancer</article-title><source>Biomaterials</source><year>2018</year><volume>154</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.10.048</pub-id><?supplied-pmid 29120816?><pub-id pub-id-type="pmid">29120816</pub-id></element-citation></ref><ref id="B14-ijms-22-09118"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVita</surname><given-names>V.T.</given-names></name><name><surname>Chu</surname><given-names>E.</given-names></name></person-group><article-title>A history of cancer chemotherapy</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>8643</fpage><lpage>8653</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6611</pub-id><?supplied-pmid 18974103?><pub-id pub-id-type="pmid">18974103</pub-id></element-citation></ref><ref id="B15-ijms-22-09118"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Villani</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Simpson</surname><given-names>M.J.</given-names></name><name><surname>Roberts</surname><given-names>M.S.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name></person-group><article-title>The role of cellular reactive oxygen species in cancer chemotherapy</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s13046-017-0664-4</pub-id><pub-id pub-id-type="pmid">29301578</pub-id></element-citation></ref><ref id="B16-ijms-22-09118"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>K.</given-names></name><name><surname>Kciuk</surname><given-names>M.</given-names></name><name><surname>Kontek</surname><given-names>R.</given-names></name></person-group><article-title>Mechanisms of multidrug resistance in cancer chemotherapy</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>3233</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21093233</pub-id><?supplied-pmid 32370233?><pub-id pub-id-type="pmid">32370233</pub-id></element-citation></ref><ref id="B17-ijms-22-09118"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name></person-group><article-title>Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00006-1</pub-id><pub-id pub-id-type="pmid">33705695</pub-id></element-citation></ref><ref id="B18-ijms-22-09118"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Ke</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Leng</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name></person-group><article-title>Breakthrough in targeted therapy for non-small cell lung cancer</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>133</volume><fpage>111079</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.111079</pub-id><pub-id pub-id-type="pmid">33378976</pub-id></element-citation></ref><ref id="B19-ijms-22-09118"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paris</surname><given-names>A.</given-names></name><name><surname>Tardif</surname><given-names>N.</given-names></name><name><surname>Galibert</surname><given-names>M.-D.</given-names></name><name><surname>Corre</surname><given-names>S.</given-names></name></person-group><article-title>AhR and cancer: From gene profiling to targeted therapy</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>752</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22020752</pub-id><?supplied-pmid 33451095?><pub-id pub-id-type="pmid">33451095</pub-id></element-citation></ref><ref id="B20-ijms-22-09118"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>G.C.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Davis</surname><given-names>J.L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Kwakwa</surname><given-names>K.A.</given-names></name><name><surname>Ross</surname><given-names>M.H.</given-names></name><name><surname>Fontana</surname><given-names>F.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Esser</surname><given-names>A.K.</given-names></name><name><surname>Cordell</surname><given-names>E.</given-names></name></person-group><article-title>Targeted therapy to &#x003b2;3 integrin reduces chemoresistance in breast cancer bone metastases</article-title><source>Mol. Cancer Ther.</source><year>2021</year><volume>20</volume><fpage>1183</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0931</pub-id><pub-id pub-id-type="pmid">33785647</pub-id></element-citation></ref><ref id="B21-ijms-22-09118"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Karzai</surname><given-names>F.</given-names></name><name><surname>Harmon</surname><given-names>S.A.</given-names></name><name><surname>Terrigino</surname><given-names>N.T.</given-names></name><name><surname>VanderWeele</surname><given-names>D.J.</given-names></name><name><surname>Bright</surname><given-names>J.R.</given-names></name><name><surname>Atway</surname><given-names>R.</given-names></name><name><surname>Trostel</surname><given-names>S.Y.</given-names></name><name><surname>Carrabba</surname><given-names>N.V.</given-names></name></person-group><article-title>Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy</article-title><source>Eur. Urol.</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.eururo.2021.03.009</pub-id><?supplied-pmid 33785256?><pub-id pub-id-type="pmid">33785256</pub-id></element-citation></ref><ref id="B22-ijms-22-09118"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.M.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name><name><surname>Chen</surname><given-names>M.F.</given-names></name><name><surname>Liu</surname><given-names>K.L.</given-names></name><name><surname>Lin</surname><given-names>C.F.</given-names></name><name><surname>Chen</surname><given-names>T.H.</given-names></name><name><surname>Wu</surname><given-names>C.T.</given-names></name></person-group><article-title>Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study</article-title><source>Prostate</source><year>2021</year><volume>81</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1002/pros.24096</pub-id><?supplied-pmid 33393676?><pub-id pub-id-type="pmid">33393676</pub-id></element-citation></ref><ref id="B23-ijms-22-09118"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>N.</given-names></name><name><surname>Sheppard</surname><given-names>N.C.</given-names></name><name><surname>Billingsley</surname><given-names>M.M.</given-names></name><name><surname>June</surname><given-names>C.H.</given-names></name><name><surname>Mitchell</surname><given-names>M.J.</given-names></name></person-group><article-title>Nanomaterials for T-cell cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><year>2021</year><volume>16</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00822-y</pub-id><pub-id pub-id-type="pmid">33437036</pub-id></element-citation></ref><ref id="B24-ijms-22-09118"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name></person-group><article-title>A DNA nanodevice-based vaccine for cancer immunotherapy</article-title><source>Nat. Mater.</source><year>2021</year><volume>20</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0793-6</pub-id><pub-id pub-id-type="pmid">32895504</pub-id></element-citation></ref><ref id="B25-ijms-22-09118"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi</surname><given-names>M.</given-names></name><name><surname>Jafari</surname><given-names>S.</given-names></name><name><surname>Hasan</surname><given-names>A.</given-names></name><name><surname>Paray</surname><given-names>B.A.</given-names></name><name><surname>Gong</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Falahati</surname><given-names>M.</given-names></name></person-group><article-title>Antimetastatic activity of lactoferrin-coated mesoporous maghemite nanoparticles in breast cancer enabled by combination therapy</article-title><source>ACS Biomater. Sci. Eng.</source><year>2020</year><volume>6</volume><fpage>3574</fpage><lpage>3584</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c00086</pub-id><pub-id pub-id-type="pmid">33463159</pub-id></element-citation></ref><ref id="B26-ijms-22-09118"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levit</surname><given-names>S.L.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name></person-group><article-title>Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer</article-title><source>Nanomaterials</source><year>2021</year><volume>11</volume><elocation-id>1048</elocation-id><pub-id pub-id-type="doi">10.3390/nano11041048</pub-id><pub-id pub-id-type="pmid">33923947</pub-id></element-citation></ref><ref id="B27-ijms-22-09118"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Imaging Beyond Seeing: Early Prognosis of Cancer Treatment</article-title><source>Small Methods</source><year>2021</year><volume>5</volume><fpage>2001025</fpage><pub-id pub-id-type="doi">10.1002/smtd.202001025</pub-id></element-citation></ref><ref id="B28-ijms-22-09118"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J.</given-names></name></person-group><article-title>Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia</article-title><source>Nat. Rev. Cardiol.</source><year>2020</year><volume>17</volume><fpage>474</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-0348-1</pub-id><pub-id pub-id-type="pmid">32231332</pub-id></element-citation></ref><ref id="B29-ijms-22-09118"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.-L.</given-names></name><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>B.-L.</given-names></name><name><surname>He</surname><given-names>W.-X.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name></person-group><article-title>Stem cells in cancer therapy: Opportunities and challenges</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>75756</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.20798</pub-id><pub-id pub-id-type="pmid">29088907</pub-id></element-citation></ref><ref id="B30-ijms-22-09118"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G.P.</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J.</given-names></name></person-group><article-title>Cancer metastasis: Building a framework</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>679</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.11.001</pub-id><pub-id pub-id-type="pmid">17110329</pub-id></element-citation></ref><ref id="B31-ijms-22-09118"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahvi</surname><given-names>D.A.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Grinstaff</surname><given-names>M.W.</given-names></name><name><surname>Colson</surname><given-names>Y.L.</given-names></name><name><surname>Raut</surname><given-names>C.P.</given-names></name></person-group><article-title>Local cancer recurrence: The realities, challenges, and opportunities for new therapies</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>488</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.3322/caac.21498</pub-id><pub-id pub-id-type="pmid">30328620</pub-id></element-citation></ref><ref id="B32-ijms-22-09118"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S.</given-names></name><name><surname>Sottoriva</surname><given-names>A.</given-names></name><name><surname>Graham</surname><given-names>T.</given-names></name><name><surname>Swanton</surname><given-names>C.</given-names></name></person-group><article-title>Resolving genetic heterogeneity in cancer</article-title><source>Nat. Rev. Genet.</source><year>2019</year><volume>20</volume><fpage>404</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0114-6</pub-id><pub-id pub-id-type="pmid">30918367</pub-id></element-citation></ref><ref id="B33-ijms-22-09118"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Liao</surname><given-names>W.</given-names></name></person-group><article-title>CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1019-x</pub-id><?supplied-pmid 31064356?><pub-id pub-id-type="pmid">31064356</pub-id></element-citation></ref><ref id="B34-ijms-22-09118"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobin</surname><given-names>E.</given-names></name><name><surname>Bagwell</surname><given-names>K.</given-names></name><name><surname>Wagner</surname><given-names>J.</given-names></name><name><surname>Mysona</surname><given-names>D.</given-names></name><name><surname>Sandirasegarane</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>N.</given-names></name><name><surname>Bai</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Schleifer</surname><given-names>R.</given-names></name><name><surname>She</surname><given-names>J.-X.</given-names></name></person-group><article-title>A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12885-019-5768-0</pub-id><pub-id pub-id-type="pmid">30606139</pub-id></element-citation></ref><ref id="B35-ijms-22-09118"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annovazzi</surname><given-names>L.</given-names></name><name><surname>Mellai</surname><given-names>M.</given-names></name><name><surname>Schiffer</surname><given-names>D.</given-names></name></person-group><article-title>Chemotherapeutic drugs: DNA damage and repair in glioblastoma</article-title><source>Cancers</source><year>2017</year><volume>9</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.3390/cancers9060057</pub-id></element-citation></ref><ref id="B36-ijms-22-09118"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhamad</surname><given-names>N.</given-names></name><name><surname>Plengsuriyakarn</surname><given-names>T.</given-names></name><name><surname>Na-Bangchang</surname><given-names>K.</given-names></name></person-group><article-title>Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>3921</fpage><pub-id pub-id-type="doi">10.2147/IJN.S165210</pub-id><?supplied-pmid 30013345?><pub-id pub-id-type="pmid">30013345</pub-id></element-citation></ref><ref id="B37-ijms-22-09118"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pich</surname><given-names>O.</given-names></name><name><surname>Mui&#x000f1;os</surname><given-names>F.</given-names></name><name><surname>Lolkema</surname><given-names>M.P.</given-names></name><name><surname>Steeghs</surname><given-names>N.</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A.</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N.</given-names></name></person-group><article-title>The mutational footprints of cancer therapies</article-title><source>Nat. Genet.</source><year>2019</year><volume>51</volume><fpage>1732</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0525-5</pub-id><?supplied-pmid 31740835?><pub-id pub-id-type="pmid">31740835</pub-id></element-citation></ref><ref id="B38-ijms-22-09118"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Khatami</surname><given-names>M.</given-names></name></person-group><article-title>Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs</article-title><source>Clin. Transl. Med.</source><year>2018</year><volume>7</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s40169-018-0185-6</pub-id><?supplied-pmid 29541939?><pub-id pub-id-type="pmid">29541939</pub-id></element-citation></ref><ref id="B39-ijms-22-09118"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Bae</surname><given-names>Y.</given-names></name><name><surname>Kasimir-Bauer</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>G.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Esposito</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>Therapeutic antibody targeting tumor-and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>731</fpage><lpage>747.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.11.002</pub-id><pub-id pub-id-type="pmid">29232552</pub-id></element-citation></ref><ref id="B40-ijms-22-09118"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larionova</surname><given-names>I.</given-names></name><name><surname>Cherdyntseva</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Patysheva</surname><given-names>M.</given-names></name><name><surname>Rakina</surname><given-names>M.</given-names></name><name><surname>Kzhyshkowska</surname><given-names>J.</given-names></name></person-group><article-title>Interaction of tumor-associated macrophages and cancer chemotherapy</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><fpage>e1596004</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2019.1596004</pub-id></element-citation></ref><ref id="B41-ijms-22-09118"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>G.S.</given-names></name><name><surname>Condeelis</surname><given-names>J.S.</given-names></name><name><surname>Oktay</surname><given-names>M.H.</given-names></name></person-group><article-title>Chemotherapy-induced metastasis: Molecular mechanisms, clinical manifestations, therapeutic interventions</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>4567</fpage><lpage>4576</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1147</pub-id><?supplied-pmid 31431464?><pub-id pub-id-type="pmid">31431464</pub-id></element-citation></ref><ref id="B42-ijms-22-09118"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lankelma</surname><given-names>J.</given-names></name><name><surname>Dekker</surname><given-names>H.</given-names></name><name><surname>Luque</surname><given-names>R.F.</given-names></name><name><surname>Luykx</surname><given-names>S.</given-names></name><name><surname>Hoekman</surname><given-names>K.</given-names></name><name><surname>Van Der Valk</surname><given-names>P.</given-names></name><name><surname>Van Diest</surname><given-names>P.J.</given-names></name><name><surname>Pinedo</surname><given-names>H.M.</given-names></name></person-group><article-title>Doxorubicin gradients in human breast cancer</article-title><source>Clin. Cancer. Res.</source><year>1999</year><volume>5</volume><fpage>1703</fpage><lpage>1707</lpage><?supplied-pmid 10430072?><pub-id pub-id-type="pmid">10430072</pub-id></element-citation></ref><ref id="B43-ijms-22-09118"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollag</surname><given-names>G.</given-names></name><name><surname>Tsai</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Ibrahim</surname><given-names>P.</given-names></name><name><surname>Nolop</surname><given-names>K.</given-names></name><name><surname>Hirth</surname><given-names>P.</given-names></name></person-group><article-title>Vemurafenib: The first drug approved for BRAF-mutant cancer</article-title><source>Nat. Rev. Drug Discov.</source><year>2012</year><volume>11</volume><fpage>873</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nrd3847</pub-id><pub-id pub-id-type="pmid">23060265</pub-id></element-citation></ref><ref id="B44-ijms-22-09118"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markman</surname><given-names>M.</given-names></name><name><surname>Mekhail</surname><given-names>T.M.</given-names></name></person-group><article-title>Paclitaxel in cancer therapy</article-title><source>Expert Opin. Pharm.</source><year>2002</year><volume>3</volume><fpage>755</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1517/14656566.3.6.755</pub-id><?supplied-pmid 12036415?><pub-id pub-id-type="pmid">12036415</pub-id></element-citation></ref><ref id="B45-ijms-22-09118"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.G.</given-names></name><name><surname>Kaufmann</surname><given-names>S.H.</given-names></name></person-group><article-title>Cancer: How does doxorubicin work?</article-title><source>Elife</source><year>2012</year><volume>1</volume><fpage>e00387</fpage><pub-id pub-id-type="doi">10.7554/eLife.00387</pub-id><?supplied-pmid 23256047?><pub-id pub-id-type="pmid">23256047</pub-id></element-citation></ref><ref id="B46-ijms-22-09118"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>M.</given-names></name></person-group><article-title>Principles of cytotoxic chemotherapy</article-title><source>Medicine</source><year>2008</year><volume>36</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.mpmed.2007.10.003</pub-id></element-citation></ref><ref id="B47-ijms-22-09118"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name></person-group><article-title>Comprehensive review of targeted therapy for colorectal cancer</article-title><source>Signal Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-0116-z</pub-id><pub-id pub-id-type="pmid">32296018</pub-id></element-citation></ref><ref id="B48-ijms-22-09118"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayati</surname><given-names>A.</given-names></name><name><surname>Moghimi</surname><given-names>S.</given-names></name><name><surname>Salarinejad</surname><given-names>S.</given-names></name><name><surname>Safavi</surname><given-names>M.</given-names></name><name><surname>Pouramiri</surname><given-names>B.</given-names></name><name><surname>Foroumadi</surname><given-names>A.</given-names></name></person-group><article-title>A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy</article-title><source>Bioorg. Chem.</source><year>2020</year><volume>99</volume><fpage>103811</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103811</pub-id><pub-id pub-id-type="pmid">32278207</pub-id></element-citation></ref><ref id="B49-ijms-22-09118"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>P.S.</given-names></name><name><surname>Chen</surname><given-names>D.S.</given-names></name></person-group><article-title>Top 10 challenges in cancer immunotherapy</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.12.011</pub-id><pub-id pub-id-type="pmid">31940268</pub-id></element-citation></ref><ref id="B50-ijms-22-09118"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>A.D.</given-names></name><name><surname>Fritz</surname><given-names>J.M.</given-names></name><name><surname>Lenardo</surname><given-names>M.J.</given-names></name></person-group><article-title>A guide to cancer immunotherapy: From T cell basic science to clinical practice</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>651</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmid">32433532</pub-id></element-citation></ref><ref id="B51-ijms-22-09118"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Cancer immunotherapy: Pros, cons and beyond</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>124</volume><fpage>109821</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.109821</pub-id><?supplied-pmid 31962285?><pub-id pub-id-type="pmid">31962285</pub-id></element-citation></ref><ref id="B52-ijms-22-09118"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Immune checkpoint signaling and cancer immunotherapy</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>660</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0343-4</pub-id><?supplied-pmid 32467592?><pub-id pub-id-type="pmid">32467592</pub-id></element-citation></ref><ref id="B53-ijms-22-09118"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>L.B.</given-names></name><name><surname>Salama</surname><given-names>A.K.</given-names></name></person-group><article-title>A review of cancer immunotherapy toxicity</article-title><source>CA Cancer J. Clin.</source><year>2020</year><volume>70</volume><fpage>86</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.3322/caac.21596</pub-id><?supplied-pmid 31944278?><pub-id pub-id-type="pmid">31944278</pub-id></element-citation></ref><ref id="B54-ijms-22-09118"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaou</surname><given-names>M.</given-names></name><name><surname>Pavlopoulou</surname><given-names>A.</given-names></name><name><surname>Georgakilas</surname><given-names>A.G.</given-names></name><name><surname>Kyrodimos</surname><given-names>E.</given-names></name></person-group><article-title>The challenge of drug resistance in cancer treatment: A current overview</article-title><source>Clin. Exp. Metastasis</source><year>2018</year><volume>35</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/s10585-018-9903-0</pub-id><?supplied-pmid 29799080?><pub-id pub-id-type="pmid">29799080</pub-id></element-citation></ref><ref id="B55-ijms-22-09118"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norouzi-Barough</surname><given-names>L.</given-names></name><name><surname>Sarookhani</surname><given-names>M.R.</given-names></name><name><surname>Sharifi</surname><given-names>M.</given-names></name><name><surname>Moghbelinejad</surname><given-names>S.</given-names></name><name><surname>Jangjoo</surname><given-names>S.</given-names></name><name><surname>Salehi</surname><given-names>R.</given-names></name></person-group><article-title>Molecular mechanisms of drug resistance in ovarian cancer</article-title><source>J. Cell. Physiol.</source><year>2018</year><volume>233</volume><fpage>4546</fpage><lpage>4562</lpage><pub-id pub-id-type="doi">10.1002/jcp.26289</pub-id><pub-id pub-id-type="pmid">29152737</pub-id></element-citation></ref><ref id="B56-ijms-22-09118"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahreddine</surname><given-names>H.</given-names></name><name><surname>Borden</surname><given-names>K.</given-names></name></person-group><article-title>Mechanisms and insights into drug resistance in cancer</article-title><source>Front. Pharmacol.</source><year>2013</year><volume>4</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.3389/fphar.2013.00028</pub-id><pub-id pub-id-type="pmid">23504227</pub-id></element-citation></ref><ref id="B57-ijms-22-09118"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavrovskaya</surname><given-names>A.</given-names></name></person-group><article-title>Cellular mechanisms of multidrug resistance of tumor cells</article-title><source>Biochem. C/C Biokhimiia</source><year>2000</year><volume>65</volume><fpage>95</fpage><lpage>106</lpage></element-citation></ref><ref id="B58-ijms-22-09118"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.-Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>F.-Q.</given-names></name></person-group><article-title>Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells</article-title><source>Int. J. Biol. Macromol.</source><year>2011</year><volume>48</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2010.11.005</pub-id><pub-id pub-id-type="pmid">21093477</pub-id></element-citation></ref><ref id="B59-ijms-22-09118"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>Q.</given-names></name><name><surname>Rousseau</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Stephens</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name></person-group><article-title>DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>96</fpage><lpage>108.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.11.006</pub-id><pub-id pub-id-type="pmid">33338425</pub-id></element-citation></ref><ref id="B60-ijms-22-09118"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peetla</surname><given-names>C.</given-names></name><name><surname>Vijayaraghavalu</surname><given-names>S.</given-names></name><name><surname>Labhasetwar</surname><given-names>V.</given-names></name></person-group><article-title>Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles</article-title><source>Adv. Drug Del. Rev.</source><year>2013</year><volume>65</volume><fpage>1686</fpage><lpage>1698</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.09.004</pub-id></element-citation></ref><ref id="B61-ijms-22-09118"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottesman</surname><given-names>M.M.</given-names></name></person-group><article-title>Mechanisms of cancer drug resistance</article-title><source>Annu. Rev. Med.</source><year>2002</year><volume>53</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.53.082901.103929</pub-id><pub-id pub-id-type="pmid">11818492</pub-id></element-citation></ref><ref id="B62-ijms-22-09118"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>B.I.</given-names></name></person-group><article-title>New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance</article-title><source>Clin. Cancer. Res.</source><year>2010</year><volume>16</volume><fpage>1348</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2273</pub-id><pub-id pub-id-type="pmid">20179240</pub-id></element-citation></ref><ref id="B63-ijms-22-09118"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lv</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xing</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Lei</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name></person-group><article-title>The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s12943-019-1086-z</pub-id><pub-id pub-id-type="pmid">30609930</pub-id></element-citation></ref><ref id="B64-ijms-22-09118"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmbach</surname><given-names>H.</given-names></name><name><surname>Rossmann</surname><given-names>E.</given-names></name><name><surname>Kern</surname><given-names>M.A.</given-names></name><name><surname>Schadendorf</surname><given-names>D.</given-names></name></person-group><article-title>Drug-resistance in human melanoma</article-title><source>Int. J. Cancer</source><year>2001</year><volume>93</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1002/ijc.1378</pub-id><pub-id pub-id-type="pmid">11477569</pub-id></element-citation></ref><ref id="B65-ijms-22-09118"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>Q.</given-names></name><name><surname>Yin</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors</article-title><source>Adv. Mater.</source><year>2016</year><volume>28</volume><fpage>9581</fpage><lpage>9588</lpage><pub-id pub-id-type="doi">10.1002/adma.201602173</pub-id><pub-id pub-id-type="pmid">27628433</pub-id></element-citation></ref><ref id="B66-ijms-22-09118"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Molecularly imprinted polymer nanoparticles: An emerging versatile platform for cancer therapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2021</year><volume>60</volume><fpage>3858</fpage><lpage>3869</lpage><pub-id pub-id-type="doi">10.1002/anie.202005309</pub-id><?supplied-pmid 32789971?><pub-id pub-id-type="pmid">32789971</pub-id></element-citation></ref><ref id="B67-ijms-22-09118"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Long</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Sheng</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.J.A.A.M.</given-names></name><etal/></person-group><article-title>Self-promoted Albumin-Based Nanoparticles for Combination Therapy against Metastatic Breast Cancer via a Hyperthermia-Induced &#x0201c;Platelet Bridge&#x0201d;</article-title><source>ACS Appl. Mater. Interfaces</source><year>2021</year><volume>13</volume><fpage>25701</fpage><lpage>25714</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c04442</pub-id><pub-id pub-id-type="pmid">34041901</pub-id></element-citation></ref><ref id="B68-ijms-22-09118"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Shim</surname><given-names>M.K.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name></person-group><article-title>Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance</article-title><source>J. Control. Release</source><year>2021</year><volume>330</volume><fpage>920</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.065</pub-id><?supplied-pmid 33152391?><pub-id pub-id-type="pmid">33152391</pub-id></element-citation></ref><ref id="B69-ijms-22-09118"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Hoque</surname><given-names>S.</given-names></name><name><surname>Tilley</surname><given-names>R.D.</given-names></name><name><surname>Gooding</surname><given-names>J.J.</given-names></name></person-group><article-title>Rapid and ultrasensitive electrochemical detection of circulating tumor DNA by hybridization on the network of gold-coated magnetic nanoparticles</article-title><source>Chem. Sci.</source><year>2021</year><volume>12</volume><fpage>5196</fpage><lpage>5201</lpage><pub-id pub-id-type="doi">10.1039/D1SC01044A</pub-id><pub-id pub-id-type="pmid">34163756</pub-id></element-citation></ref><ref id="B70-ijms-22-09118"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>P.</given-names></name><name><surname>Kathuria</surname><given-names>H.</given-names></name><name><surname>Momin</surname><given-names>M.</given-names></name></person-group><article-title>Clinical therapies and nano drug delivery systems for urinary bladder cancer</article-title><source>Pharmacol. Ther.</source><year>2021</year><volume>226</volume><fpage>107871</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107871</pub-id><?supplied-pmid 33915179?><pub-id pub-id-type="pmid">33915179</pub-id></element-citation></ref><ref id="B71-ijms-22-09118"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group><article-title>Layer-by-Layer assembled nano-drug delivery systems for cancer treatment</article-title><source>Drug Deliv.</source><year>2021</year><volume>28</volume><fpage>655</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1080/10717544.2021.1905748</pub-id><?supplied-pmid 33787431?><pub-id pub-id-type="pmid">33787431</pub-id></element-citation></ref><ref id="B72-ijms-22-09118"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaman</surname><given-names>D.&#x0015e;.</given-names></name><name><surname>Kaasalainen</surname><given-names>M.</given-names></name><name><surname>Kettiger</surname><given-names>H.</given-names></name><name><surname>Rosenholm</surname><given-names>J.M.</given-names></name></person-group><article-title>Opportunities and Challenges of Silicon-based Nanoparticles for Drug Delivery and Imaging</article-title><source>Charact. Pharm. Nano Microsyst.</source><year>2021</year><volume>9</volume><fpage>291</fpage><lpage>337</lpage></element-citation></ref><ref id="B73-ijms-22-09118"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sponchioni</surname><given-names>M.</given-names></name><name><surname>Palmiero</surname><given-names>U.C.</given-names></name><name><surname>Moscatelli</surname><given-names>D.</given-names></name></person-group><article-title>Thermo-responsive polymers: Applications of smart materials in drug delivery and tissue engineering</article-title><source>Mater. Sci. Eng. C</source><year>2019</year><volume>102</volume><fpage>589</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.04.069</pub-id></element-citation></ref><ref id="B74-ijms-22-09118"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasher</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>S.P.</given-names></name></person-group><article-title>Drug encapsulating polysaccharide-loaded metal nanoparticles: A perspective drug delivery system</article-title><source>Drug Dev. Res.</source><year>2021</year><volume>82</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1002/ddr.21754</pub-id><pub-id pub-id-type="pmid">33137245</pub-id></element-citation></ref><ref id="B75-ijms-22-09118"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichaita</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>Y.-G.</given-names></name><name><surname>Tangboriboonrat</surname><given-names>P.</given-names></name><name><surname>Th&#x000e9;rien-Aubin</surname><given-names>H.</given-names></name></person-group><article-title>Polymer-functionalized polymer nanoparticles and their behaviour in suspensions</article-title><source>Polym. Chem.</source><year>2020</year><volume>11</volume><fpage>2119</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1039/C9PY01558B</pub-id></element-citation></ref><ref id="B76-ijms-22-09118"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Ran</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Polymer-functionalized mesoporous carbon nanoparticles on overcoming multiple barriers and improving oral bioavailability of Probucol</article-title><source>Carbohydr. Polym.</source><year>2020</year><volume>229</volume><fpage>115508</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115508</pub-id><pub-id pub-id-type="pmid">31826471</pub-id></element-citation></ref><ref id="B77-ijms-22-09118"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zieli&#x00144;ska</surname><given-names>A.</given-names></name><name><surname>Skwarek</surname><given-names>E.</given-names></name><name><surname>Zaleska</surname><given-names>A.</given-names></name><name><surname>Gazda</surname><given-names>M.</given-names></name><name><surname>Hupka</surname><given-names>J.</given-names></name></person-group><article-title>Preparation of silver nanoparticles with controlled particle size</article-title><source>Procedia Chem.</source><year>2009</year><volume>1</volume><fpage>1560</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1016/j.proche.2009.11.004</pub-id></element-citation></ref><ref id="B78-ijms-22-09118"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ea;s</surname><given-names>A.</given-names></name><name><surname>Amaral</surname><given-names>M.</given-names></name><name><surname>Lobo</surname><given-names>J.S.</given-names></name><name><surname>Silva</surname><given-names>A.C.</given-names></name></person-group><article-title>Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review</article-title><source>Eur. J. Pharm. Sci.</source><year>2018</year><volume>112</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2017.11.023</pub-id><pub-id pub-id-type="pmid">29183800</pub-id></element-citation></ref><ref id="B79-ijms-22-09118"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>R.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>Self-healing of electrical damage in polymers using superparamagnetic nanoparticles</article-title><source>Nat. Nanotechnol.</source><year>2019</year><volume>14</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/s41565-018-0327-4</pub-id><pub-id pub-id-type="pmid">30598524</pub-id></element-citation></ref><ref id="B80-ijms-22-09118"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Phua</surname><given-names>S.Z.F.</given-names></name><name><surname>Bindra</surname><given-names>A.K.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Degradability and clearance of inorganic nanoparticles for biomedical applications</article-title><source>Adv. Mater.</source><year>2019</year><volume>31</volume><fpage>1805730</fpage><pub-id pub-id-type="doi">10.1002/adma.201805730</pub-id></element-citation></ref><ref id="B81-ijms-22-09118"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Douthwaite</surname><given-names>M.</given-names></name><name><surname>Pattisson</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>Z.</given-names></name></person-group><article-title>Recent advances in the catalytic oxidation of volatile organic compounds: A review based on pollutant sorts and sources</article-title><source>Chem. Rev.</source><year>2019</year><volume>119</volume><fpage>4471</fpage><lpage>4568</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00408</pub-id><pub-id pub-id-type="pmid">30811934</pub-id></element-citation></ref><ref id="B82-ijms-22-09118"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamkhande</surname><given-names>P.G.</given-names></name><name><surname>Ghule</surname><given-names>N.W.</given-names></name><name><surname>Bamer</surname><given-names>A.H.</given-names></name><name><surname>Kalaskar</surname><given-names>M.G.</given-names></name></person-group><article-title>Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2019</year><volume>53</volume><fpage>101174</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101174</pub-id></element-citation></ref><ref id="B83-ijms-22-09118"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>P.M.</given-names></name><name><surname>Muzykantov</surname><given-names>V.R.J.J.o.P.</given-names></name><name><surname>Therapeutics</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic properties of drug delivery systems</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2019</year><volume>370</volume><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1124/jpet.119.257113</pub-id><pub-id pub-id-type="pmid">30837281</pub-id></element-citation></ref><ref id="B84-ijms-22-09118"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouaib</surname><given-names>R.</given-names></name><name><surname>Sarieddine</surname><given-names>R.</given-names></name><name><surname>Gali-Muhtasib</surname><given-names>H.</given-names></name></person-group><article-title>Nanoparticles as Drug Delivery Systems for Cancer Treatment: Applications in Targeted Therapy and Personalized Medicine</article-title><source>Nanopart. Drug Deliv. Syst. Cancer Treat.</source><year>2020</year><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="B85-ijms-22-09118"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudhipala</surname><given-names>N.</given-names></name><name><surname>Gorre</surname><given-names>T.</given-names></name></person-group><article-title>Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for parkinson&#x02019;s disease: In vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>448</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12050448</pub-id></element-citation></ref><ref id="B86-ijms-22-09118"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukhanova</surname><given-names>A.</given-names></name><name><surname>Bozrova</surname><given-names>S.</given-names></name><name><surname>Sokolov</surname><given-names>P.</given-names></name><name><surname>Berestovoy</surname><given-names>M.</given-names></name><name><surname>Karaulov</surname><given-names>A.</given-names></name><name><surname>Nabiev</surname><given-names>I.</given-names></name></person-group><article-title>Dependence of nanoparticle toxicity on their physical and chemical properties</article-title><source>Nanoscale Res. Lett.</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1186/s11671-018-2457-x</pub-id><?supplied-pmid 29417375?><pub-id pub-id-type="pmid">29299709</pub-id></element-citation></ref><ref id="B87-ijms-22-09118"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Preparation, characteristics and antioxidant activity of polysaccharides and proteins-capped selenium nanoparticles synthesized by Lactobacillus casei ATCC 393</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>195</volume><fpage>576</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2018.04.110</pub-id><pub-id pub-id-type="pmid">29805014</pub-id></element-citation></ref><ref id="B88-ijms-22-09118"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kister</surname><given-names>T.</given-names></name><name><surname>Monego</surname><given-names>D.</given-names></name><name><surname>Mulvaney</surname><given-names>P.</given-names></name><name><surname>Widmer-Cooper</surname><given-names>A.</given-names></name><name><surname>Kraus</surname><given-names>T.</given-names></name></person-group><article-title>Colloidal stability of apolar nanoparticles: The role of particle size and ligand shell structure</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>5969</fpage><lpage>5977</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b02202</pub-id><pub-id pub-id-type="pmid">29842786</pub-id></element-citation></ref><ref id="B89-ijms-22-09118"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinson</surname><given-names>J.</given-names></name><name><surname>Inaba</surname><given-names>M.</given-names></name><name><surname>Neumann</surname><given-names>S.</given-names></name><name><surname>Swane</surname><given-names>A.A.</given-names></name><name><surname>Bucher</surname><given-names>J.</given-names></name><name><surname>Simonsen</surname><given-names>S.B.</given-names></name><name><surname>Theil Kuhn</surname><given-names>L.</given-names></name><name><surname>Kirkensgaard</surname><given-names>J.J.</given-names></name><name><surname>Jensen</surname><given-names>K.M.</given-names></name><name><surname>Oezaslan</surname><given-names>M.</given-names></name></person-group><article-title>Investigating particle size effects in catalysis by applying a size-controlled and surfactant-free synthesis of colloidal nanoparticles in alkaline ethylene glycol: Case study of the oxygen reduction reaction on Pt</article-title><source>ACS Catal.</source><year>2018</year><volume>8</volume><fpage>6627</fpage><lpage>6635</lpage><pub-id pub-id-type="doi">10.1021/acscatal.8b00694</pub-id></element-citation></ref><ref id="B90-ijms-22-09118"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caster</surname><given-names>J.M.</given-names></name><name><surname>Stephanie</surname><given-names>K.Y.</given-names></name><name><surname>Patel</surname><given-names>A.N.</given-names></name><name><surname>Newman</surname><given-names>N.J.</given-names></name><name><surname>Lee</surname><given-names>Z.J.</given-names></name><name><surname>Warner</surname><given-names>S.B.</given-names></name><name><surname>Wagner</surname><given-names>K.T.</given-names></name><name><surname>Roche</surname><given-names>K.C.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Min</surname><given-names>Y.</given-names></name></person-group><article-title>Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2017</year><volume>13</volume><fpage>1673</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.03.002</pub-id></element-citation></ref><ref id="B91-ijms-22-09118"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Holden</surname><given-names>J.A.</given-names></name><name><surname>Heath</surname><given-names>D.E.</given-names></name><name><surname>O&#x02019;Brien-Simpson</surname><given-names>N.M.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>A.J.</given-names></name></person-group><article-title>Engineering highly effective antimicrobial selenium nanoparticles through control of particle size</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><fpage>14937</fpage><lpage>14951</lpage><pub-id pub-id-type="doi">10.1039/C9NR04424H</pub-id><pub-id pub-id-type="pmid">31363721</pub-id></element-citation></ref><ref id="B92-ijms-22-09118"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>M.C.</given-names></name><name><surname>White</surname><given-names>E.L.</given-names></name><name><surname>Boley</surname><given-names>J.W.</given-names></name><name><surname>Deng</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>G.J.</given-names></name><name><surname>Kramer-Bottiglio</surname><given-names>R.</given-names></name></person-group><article-title>Laser sintering of liquid metal nanoparticles for scalable manufacturing of soft and flexible electronics</article-title><source>ACS Appl. Mater. Interfaces</source><year>2018</year><volume>10</volume><fpage>28232</fpage><lpage>28241</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b08722</pub-id><pub-id pub-id-type="pmid">30045618</pub-id></element-citation></ref><ref id="B93-ijms-22-09118"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grodzinski</surname><given-names>P.</given-names></name><name><surname>Silver</surname><given-names>M.</given-names></name><name><surname>Molnar</surname><given-names>L.K.</given-names></name></person-group><article-title>Nanotechnology for cancer diagnostics: Promises and challenges</article-title><source>Expert Rev. Mol. Diagn.</source><year>2006</year><volume>6</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1586/14737159.6.3.307</pub-id><pub-id pub-id-type="pmid">16706735</pub-id></element-citation></ref><ref id="B94-ijms-22-09118"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.-D.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacokinetics and biodistribution of nanoparticles</article-title><source>Mol. Pharm.</source><year>2008</year><volume>5</volume><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1021/mp800049w</pub-id><pub-id pub-id-type="pmid">18611037</pub-id></element-citation></ref><ref id="B95-ijms-22-09118"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>552</volume><fpage>328</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.10.011</pub-id><pub-id pub-id-type="pmid">30308270</pub-id></element-citation></ref><ref id="B96-ijms-22-09118"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anchordoquy</surname><given-names>T.J.</given-names></name><name><surname>Barenholz</surname><given-names>Y.</given-names></name><name><surname>Boraschi</surname><given-names>D.</given-names></name><name><surname>Chorny</surname><given-names>M.</given-names></name><name><surname>Decuzzi</surname><given-names>P.</given-names></name><name><surname>Dobrovolskaia</surname><given-names>M.A.</given-names></name><name><surname>Farhangrazi</surname><given-names>Z.S.</given-names></name><name><surname>Farrell</surname><given-names>D.</given-names></name><name><surname>Gabizon</surname><given-names>A.</given-names></name><name><surname>Ghandehari</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b08244</pub-id><pub-id pub-id-type="pmid">28068099</pub-id></element-citation></ref><ref id="B97-ijms-22-09118"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petros</surname><given-names>R.A.</given-names></name><name><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Strategies in the design of nanoparticles for therapeutic applications</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/nrd2591</pub-id><pub-id pub-id-type="pmid">20616808</pub-id></element-citation></ref><ref id="B98-ijms-22-09118"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastgar</surname><given-names>M.</given-names></name><name><surname>Shakeri</surname><given-names>A.</given-names></name><name><surname>Bozorg</surname><given-names>A.</given-names></name><name><surname>Salehi</surname><given-names>H.</given-names></name><name><surname>Saadattalab</surname><given-names>V.</given-names></name></person-group><article-title>Impact of nanoparticles surface characteristics on pore structure and performance of forward osmosis membranes</article-title><source>Desalination</source><year>2017</year><volume>421</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.desal.2017.01.040</pub-id></element-citation></ref><ref id="B99-ijms-22-09118"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L.</given-names></name><name><surname>Liang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Mechanisms that control the adsorption&#x02013;desorption behavior of phosphate on magnetite nanoparticles: The role of particle size and surface chemistry characteristics</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><fpage>2378</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1039/C9RA08517C</pub-id></element-citation></ref><ref id="B100-ijms-22-09118"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Settanni</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Suo</surname><given-names>T.</given-names></name><name><surname>Sch&#x000f6;ttler</surname><given-names>S.</given-names></name><name><surname>Landfester</surname><given-names>K.</given-names></name><name><surname>Schmid</surname><given-names>F.</given-names></name><name><surname>Mail&#x000e4;nder</surname><given-names>V.</given-names></name></person-group><article-title>Protein corona composition of poly (ethylene glycol)-and poly (phosphoester)-coated nanoparticles correlates strongly with the amino acid composition of the protein surface</article-title><source>Nanoscale</source><year>2017</year><volume>9</volume><fpage>2138</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1039/C6NR07022A</pub-id><pub-id pub-id-type="pmid">28124700</pub-id></element-citation></ref><ref id="B101-ijms-22-09118"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partikel</surname><given-names>K.</given-names></name><name><surname>Korte</surname><given-names>R.</given-names></name><name><surname>Stein</surname><given-names>N.C.</given-names></name><name><surname>Mulac</surname><given-names>D.</given-names></name><name><surname>Herrmann</surname><given-names>F.C.</given-names></name><name><surname>Humpf</surname><given-names>H.-U.</given-names></name><name><surname>Langer</surname><given-names>K.</given-names></name></person-group><article-title>Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2019</year><volume>141</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2019.05.006</pub-id><pub-id pub-id-type="pmid">31082511</pub-id></element-citation></ref><ref id="B102-ijms-22-09118"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Tong</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Ouyang</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Tumor Microenvironment-Responsive Dual Drug Dimer-Loaded PEGylated Bilirubin Nanoparticles for Improved Drug Delivery and Enhanced Immune-Chemotherapy of Breast Cancer</article-title><source>Adv. Funct. Mater.</source><year>2019</year><volume>29</volume><fpage>1901896</fpage><pub-id pub-id-type="doi">10.1002/adfm.201901896</pub-id></element-citation></ref><ref id="B103-ijms-22-09118"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Influence of ligands property and particle size of gold nanoparticles on the protein adsorption and corresponding targeting ability</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>538</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.01.011</pub-id><?supplied-pmid 29341915?><pub-id pub-id-type="pmid">29341915</pub-id></element-citation></ref><ref id="B104-ijms-22-09118"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patsula</surname><given-names>V.</given-names></name><name><surname>Hor&#x000e1;k</surname><given-names>D.</given-names></name><name><surname>Ku&#x0010d;ka</surname><given-names>J.</given-names></name><name><surname>Mackov&#x000e1;</surname><given-names>H.</given-names></name><name><surname>Lobaz</surname><given-names>V.</given-names></name><name><surname>Francov&#x000e1;</surname><given-names>P.</given-names></name><name><surname>Herynek</surname><given-names>V.</given-names></name><name><surname>Heizer</surname><given-names>T.</given-names></name><name><surname>P&#x000e1;ral</surname><given-names>P.</given-names></name><name><surname>&#x00160;efc</surname><given-names>L.</given-names></name></person-group><article-title>Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-47262-w</pub-id><?supplied-pmid 31341232?><pub-id pub-id-type="pmid">30626917</pub-id></element-citation></ref><ref id="B105-ijms-22-09118"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>T.</given-names></name><name><surname>Stolnik</surname><given-names>S.</given-names></name><name><surname>Heald</surname><given-names>C.</given-names></name><name><surname>Xiong</surname><given-names>C.</given-names></name><name><surname>Garnett</surname><given-names>M.</given-names></name><name><surname>Illum</surname><given-names>L.</given-names></name><name><surname>Davis</surname><given-names>S.</given-names></name><name><surname>Purkiss</surname><given-names>S.</given-names></name><name><surname>Barlow</surname><given-names>R.</given-names></name><name><surname>Gellert</surname><given-names>P.</given-names></name></person-group><article-title>Physicochemical evaluation of nanoparticles assembled from Poly (lactic acid)&#x02212;Poly (ethylene glycol)(PLA&#x02212;PEG) block copolymers as drug delivery vehicles</article-title><source>Langmuir</source><year>2001</year><volume>17</volume><fpage>3168</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1021/la001226i</pub-id></element-citation></ref><ref id="B106-ijms-22-09118"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.-Y.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.-Q.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>H.-W.</given-names></name></person-group><article-title>Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapy</article-title><source>Acta Biomater.</source><year>2020</year><volume>112</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.05.028</pub-id><pub-id pub-id-type="pmid">32470527</pub-id></element-citation></ref><ref id="B107-ijms-22-09118"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.-M.J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Aryal</surname><given-names>S.</given-names></name><name><surname>Cheung</surname><given-names>C.</given-names></name><name><surname>Fang</surname><given-names>R.H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>10980</fpage><lpage>10985</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106634108</pub-id><pub-id pub-id-type="pmid">21690347</pub-id></element-citation></ref><ref id="B108-ijms-22-09118"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>E.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmid">26348965</pub-id></element-citation></ref><ref id="B109-ijms-22-09118"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Smart polymeric nanoparticles for cancer gene delivery</article-title><source>Mol. Pharm.</source><year>2015</year><volume>12</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1021/mp500656v</pub-id><pub-id pub-id-type="pmid">25531409</pub-id></element-citation></ref><ref id="B110-ijms-22-09118"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name></person-group><article-title>Tumor microenvironment-induced structure changing drug/gene delivery system for overcoming delivery-associated challenges</article-title><source>J. Control. Release</source><year>2020</year><volume>323</volume><fpage>203</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.04.026</pub-id><pub-id pub-id-type="pmid">32320817</pub-id></element-citation></ref><ref id="B111-ijms-22-09118"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Tao</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy</article-title><source>Drug Deliv.</source><year>2021</year><volume>28</volume><fpage>594</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1080/10717544.2021.1898703</pub-id><pub-id pub-id-type="pmid">33729072</pub-id></element-citation></ref><ref id="B112-ijms-22-09118"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>Systemic Nanoparticle-Mediated Delivery of Pantetheinase Vanin-1 Regulates Lipolysis and Adiposity in Abdominal White Adipose Tissue</article-title><source>Adv. Sci. (Weinh)</source><year>2020</year><volume>7</volume><fpage>2000542</fpage><pub-id pub-id-type="doi">10.1002/advs.202000542</pub-id><pub-id pub-id-type="pmid">32714762</pub-id></element-citation></ref><ref id="B113-ijms-22-09118"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>K.T.</given-names></name></person-group><article-title>Targeted Nanoparticles for Cancer Therapy: Promises and Challenges</article-title><source>J. Nanomed. Nanotechnol.</source><year>2011</year><volume>2</volume><fpage>1000103e</fpage><pub-id pub-id-type="doi">10.4172/2157-7439.1000103e</pub-id></element-citation></ref><ref id="B114-ijms-22-09118"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>R.</given-names></name></person-group><article-title>pH-sensitive bromelain nanoparticles by ortho ester crosslinkage for enhanced doxorubicin penetration in solid tumor</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><year>2020</year><volume>113</volume><fpage>111004</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111004</pub-id><pub-id pub-id-type="pmid">32487411</pub-id></element-citation></ref><ref id="B115-ijms-22-09118"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cong</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name></person-group><article-title>Liposomes modified with bio-substances for cancer treatment</article-title><source>Biomater. Sci.</source><year>2020</year><volume>8</volume><fpage>6442</fpage><lpage>6468</lpage><pub-id pub-id-type="doi">10.1039/D0BM01531H</pub-id><pub-id pub-id-type="pmid">33107517</pub-id></element-citation></ref><ref id="B116-ijms-22-09118"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>Y.-T.</given-names></name><name><surname>Lo</surname><given-names>C.-L.</given-names></name></person-group><article-title>pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>5414</fpage><lpage>5424</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.03.046</pub-id><pub-id pub-id-type="pmid">24709521</pub-id></element-citation></ref><ref id="B117-ijms-22-09118"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>Y.J.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Surface charge switchable polymer/DNA nanoparticles responsive to tumor extracellular ph for tumor-triggered enhanced gene delivery</article-title><source>Biomacromolecules</source><year>2020</year><volume>21</volume><fpage>1136</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.9b01521</pub-id><pub-id pub-id-type="pmid">31944668</pub-id></element-citation></ref><ref id="B118-ijms-22-09118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.-K.</given-names></name><name><surname>Huang</surname><given-names>P.-K.</given-names></name><name><surname>Law</surname><given-names>W.-C.</given-names></name><name><surname>Chu</surname><given-names>C.-H.</given-names></name><name><surname>Chen</surname><given-names>N.-T.</given-names></name><name><surname>Lo</surname><given-names>L.-W.</given-names></name></person-group><article-title>Biodegradable polymers for gene-delivery applications</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>2131</fpage><pub-id pub-id-type="doi">10.2147/IJN.S222419</pub-id></element-citation></ref><ref id="B119-ijms-22-09118"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Z.</given-names></name><name><surname>Wong</surname><given-names>S.W.</given-names></name><name><surname>Yeo</surname><given-names>H.L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Nanocarriers for cancer treatment: Clinical impact and safety</article-title><source>NanoImpact</source><year>2020</year><volume>20</volume><fpage>100253</fpage><pub-id pub-id-type="doi">10.1016/j.impact.2020.100253</pub-id></element-citation></ref><ref id="B120-ijms-22-09118"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfram</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Gentile</surname><given-names>E.</given-names></name><name><surname>Paolino</surname><given-names>D.</given-names></name><name><surname>Fresta</surname><given-names>M.</given-names></name><name><surname>Nie</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name></person-group><article-title>Safety of nanoparticles in medicine</article-title><source>Curr. Drug Targets</source><year>2015</year><volume>16</volume><fpage>1671</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.2174/1389450115666140804124808</pub-id><pub-id pub-id-type="pmid">26601723</pub-id></element-citation></ref><ref id="B121-ijms-22-09118"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocan</surname><given-names>T.</given-names></name><name><surname>Clichici</surname><given-names>S.</given-names></name><name><surname>Ago&#x0015f;ton-Coldea</surname><given-names>L.</given-names></name><name><surname>Mocan</surname><given-names>L.</given-names></name><name><surname>&#x0015e;imon</surname><given-names>&#x0015e;.</given-names></name><name><surname>Ilie</surname><given-names>I.</given-names></name><name><surname>Biri&#x0015f;</surname><given-names>A.</given-names></name><name><surname>Mure&#x0015f;an</surname><given-names>A.</given-names></name></person-group><article-title>Implications of oxidative stress mechanisms in toxicity of nanoparticles</article-title><source>Acta Physiol. Hung.</source><year>2010</year><volume>97</volume><fpage>247</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1556/APhysiol.97.2010.3.1</pub-id><pub-id pub-id-type="pmid">20843763</pub-id></element-citation></ref><ref id="B122-ijms-22-09118"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Hung</surname><given-names>T.T.</given-names></name><name><surname>Stenzel</surname><given-names>M.H.</given-names></name></person-group><article-title>Safety of nanoparticles based on albumin&#x02013;polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy</article-title><source>J. Mater. Chem. B</source><year>2018</year><volume>6</volume><fpage>6278</fpage><lpage>6287</lpage><pub-id pub-id-type="doi">10.1039/C8TB01613E</pub-id><pub-id pub-id-type="pmid">32254618</pub-id></element-citation></ref><ref id="B123-ijms-22-09118"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>J.W.</given-names></name><name><surname>Santos</surname><given-names>J.L.</given-names></name><name><surname>Williford</surname><given-names>J.-M.</given-names></name><name><surname>Mao</surname><given-names>H.-Q.</given-names></name></person-group><article-title>Control of polymeric nanoparticle size to improve therapeutic delivery</article-title><source>J. Control. Release</source><year>2015</year><volume>219</volume><fpage>536</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.10.006</pub-id><?supplied-pmid 26450667?><pub-id pub-id-type="pmid">26450667</pub-id></element-citation></ref><ref id="B124-ijms-22-09118"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielinska</surname><given-names>A.</given-names></name><name><surname>Carreiro</surname><given-names>F.</given-names></name><name><surname>Oliveira</surname><given-names>A.M.</given-names></name><name><surname>Neves</surname><given-names>A.</given-names></name><name><surname>Pires</surname><given-names>B.</given-names></name><name><surname>Venkatesh</surname><given-names>D.N.</given-names></name><name><surname>Durazzo</surname><given-names>A.</given-names></name><name><surname>Lucarini</surname><given-names>M.</given-names></name><name><surname>Eder</surname><given-names>P.</given-names></name><name><surname>Silva</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3731</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25163731</pub-id></element-citation></ref><ref id="B125-ijms-22-09118"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>T.</given-names></name><name><surname>Bernfur</surname><given-names>K.</given-names></name><name><surname>Vilanova</surname><given-names>M.</given-names></name><name><surname>Cedervall</surname><given-names>T.</given-names></name></person-group><article-title>Understanding the lipid and protein corona formation on different sized polymeric nanoparticles</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-57943-6</pub-id><?supplied-pmid 31980686?><pub-id pub-id-type="pmid">31913322</pub-id></element-citation></ref><ref id="B126-ijms-22-09118"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Baby</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Weitz</surname><given-names>D.A.</given-names></name><name><surname>Zhao</surname><given-names>C.X.</given-names></name></person-group><article-title>Stable polymer nanoparticles with exceptionally high drug loading by sequential nanoprecipitation</article-title><source>Angew. Chem.</source><year>2020</year><volume>132</volume><fpage>4750</fpage><lpage>4758</lpage><pub-id pub-id-type="doi">10.1002/ange.201913539</pub-id></element-citation></ref><ref id="B127-ijms-22-09118"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Tocilizumab&#x02013;Conjugated Polymer Nanoparticles for NIR-II Photoacoustic-Imaging-Guided Therapy of Rheumatoid Arthritis</article-title><source>Adv. Mater.</source><year>2020</year><volume>32</volume><fpage>2003399</fpage><pub-id pub-id-type="doi">10.1002/adma.202003399</pub-id><?supplied-pmid 32743864?><pub-id pub-id-type="pmid">32743864</pub-id></element-citation></ref><ref id="B128-ijms-22-09118"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>You</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>G.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name></person-group><article-title>Carbon dots sensitized lanthanide infinite coordination polymer nanoparticles: Towards ratiometric fluorescent sensing of cerebrospinal A&#x003b2; monomer as a biomarker for Alzheimer&#x02019;s disease</article-title><source>Anal. Chim. Acta</source><year>2020</year><volume>1105</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2020.01.021</pub-id><pub-id pub-id-type="pmid">32138913</pub-id></element-citation></ref><ref id="B129-ijms-22-09118"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Gong</surname><given-names>R.</given-names></name></person-group><article-title>Carboxymethyl-&#x003b2;-cyclodextrin grafted chitosan nanoparticles as oral delivery carrier of protein drugs</article-title><source>React. Funct. Polym.</source><year>2017</year><volume>117</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.reactfunctpolym.2017.05.008</pub-id></element-citation></ref><ref id="B130-ijms-22-09118"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>K.</given-names></name><name><surname>Hou</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Cross-linked chitosan/&#x003b2;-cyclodextrin composite for selective removal of methyl orange: Adsorption performance and mechanism</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>182</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2017.10.097</pub-id><pub-id pub-id-type="pmid">29279104</pub-id></element-citation></ref><ref id="B131-ijms-22-09118"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhar</surname><given-names>S.</given-names></name><name><surname>Gu</surname><given-names>F.X.</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name><name><surname>Farokhzad</surname><given-names>O.C.</given-names></name><name><surname>Lippard</surname><given-names>S.J.</given-names></name></person-group><article-title>Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA&#x02013;PEG nanoparticles</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>17356</fpage><lpage>17361</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809154105</pub-id><pub-id pub-id-type="pmid">18978032</pub-id></element-citation></ref><ref id="B132-ijms-22-09118"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Kope&#x0010d;ek</surname><given-names>J.</given-names></name></person-group><article-title>The light at the end of the tunnel&#x02014;Second generation HPMA conjugates for cancer treatment</article-title><source>Curr. Opin. Colloid Interface Sci.</source><year>2017</year><volume>31</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.cocis.2017.07.003</pub-id><?supplied-pmid 29276426?><pub-id pub-id-type="pmid">29276426</pub-id></element-citation></ref><ref id="B133-ijms-22-09118"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muss</surname><given-names>H.B.</given-names></name><name><surname>Cooper</surname><given-names>M.R.</given-names></name><name><surname>Brockschmidt</surname><given-names>J.K.</given-names></name><name><surname>Ferree</surname><given-names>C.</given-names></name><name><surname>Richards</surname><given-names>F.</given-names></name><name><surname>White</surname><given-names>D.R.</given-names></name><name><surname>Jackson</surname><given-names>D.V.</given-names></name><name><surname>Spurr</surname><given-names>C.L.</given-names></name></person-group><article-title>A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer</article-title><source>Breast Cancer Res. Treat.</source><year>1991</year><volume>19</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/BF01980937</pub-id><?supplied-pmid 1756271?><pub-id pub-id-type="pmid">1756271</pub-id></element-citation></ref><ref id="B134-ijms-22-09118"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordat</surname><given-names>A.</given-names></name><name><surname>Boissenot</surname><given-names>T.</given-names></name><name><surname>Nicolas</surname><given-names>J.</given-names></name><name><surname>Tsapis</surname><given-names>N.</given-names></name></person-group><article-title>Thermoresponsive polymer nanocarriers for biomedical applications</article-title><source>Adv. Drug Del. Rev.</source><year>2019</year><volume>138</volume><fpage>167</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2018.10.005</pub-id><?supplied-pmid 30315832?><pub-id pub-id-type="pmid">30315832</pub-id></element-citation></ref><ref id="B135-ijms-22-09118"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Willis</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>J.E.</given-names></name><name><surname>Lyle</surname><given-names>L.T.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Yeo</surname><given-names>Y.</given-names></name></person-group><article-title>Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors</article-title><source>Biomaterials</source><year>2018</year><volume>180</volume><fpage>206</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.07.024</pub-id><pub-id pub-id-type="pmid">30048910</pub-id></element-citation></ref><ref id="B136-ijms-22-09118"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subjakova</surname><given-names>V.</given-names></name><name><surname>Oravczova</surname><given-names>V.</given-names></name><name><surname>Hianik</surname><given-names>T.</given-names></name></person-group><article-title>Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer</article-title><source>Polymers</source><year>2021</year><volume>13</volume><elocation-id>341</elocation-id><pub-id pub-id-type="doi">10.3390/polym13030341</pub-id><pub-id pub-id-type="pmid">33494545</pub-id></element-citation></ref><ref id="B137-ijms-22-09118"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Nanocarrier-Based Drug Delivery for Melanoma Therapeutics</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1873</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22041873</pub-id><pub-id pub-id-type="pmid">33668591</pub-id></element-citation></ref><ref id="B138-ijms-22-09118"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>D.</given-names></name><name><surname>Calvo</surname><given-names>J.A.</given-names></name><name><surname>Samson</surname><given-names>L.D.</given-names></name></person-group><article-title>Balancing repair and tolerance of DNA damage caused by alkylating agents</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>104</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nrc3185</pub-id><?supplied-pmid 22237395?><pub-id pub-id-type="pmid">22237395</pub-id></element-citation></ref><ref id="B139-ijms-22-09118"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>R.L.</given-names></name><name><surname>M&#x000fc;nz</surname><given-names>F.</given-names></name><name><surname>Vidoni</surname><given-names>D.</given-names></name><name><surname>R&#x000fc;hle</surname><given-names>A.</given-names></name><name><surname>Trinh</surname><given-names>T.</given-names></name><name><surname>Sisombath</surname><given-names>S.</given-names></name><name><surname>Zou</surname><given-names>B.</given-names></name><name><surname>Wuchter</surname><given-names>P.</given-names></name><name><surname>Debus</surname><given-names>J.</given-names></name><name><surname>Grosu</surname><given-names>A.-L.</given-names></name></person-group><article-title>Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy</article-title><source>Stem Cell Res.</source><year>2019</year><volume>40</volume><fpage>101536</fpage><pub-id pub-id-type="doi">10.1016/j.scr.2019.101536</pub-id><pub-id pub-id-type="pmid">31437767</pub-id></element-citation></ref><ref id="B140-ijms-22-09118"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenconi</surname><given-names>E.</given-names></name><name><surname>Rigali</surname><given-names>S.</given-names></name></person-group><article-title>Self-resistance mechanisms to DNA-damaging antitumor antibiotics in actinobacteria</article-title><source>Curr. Opin. Microbiol.</source><year>2018</year><volume>45</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.03.003</pub-id><pub-id pub-id-type="pmid">29642052</pub-id></element-citation></ref><ref id="B141-ijms-22-09118"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.-f.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>X.-q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>S.-c.</given-names></name><name><surname>Luo</surname><given-names>Y.-y.</given-names></name><name><surname>Zhang</surname><given-names>J.-m.</given-names></name><name><surname>Fu</surname><given-names>C.-m.</given-names></name></person-group><article-title>Antitumor status analysis on the co-delivery systems regarding the active ingredients of Chinese herbs combined with chemotherapeutic drugs</article-title><source>Acta Pharm. Sin.</source><year>2019</year><volume>54</volume><fpage>258</fpage><lpage>268</lpage></element-citation></ref><ref id="B142-ijms-22-09118"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lissoni</surname><given-names>P.</given-names></name><name><surname>Rovelli</surname><given-names>F.</given-names></name><name><surname>Brivio</surname><given-names>F.</given-names></name><name><surname>Messina</surname><given-names>G.</given-names></name><name><surname>Lissoni</surname><given-names>A.</given-names></name><name><surname>Pensato</surname><given-names>S.</given-names></name><name><surname>Di Fede</surname><given-names>G.</given-names></name></person-group><article-title>Five year-survivals with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible for the only palliative therapy</article-title><source>Res. J. Oncol.</source><year>2018</year><volume>2</volume><fpage>2</fpage></element-citation></ref><ref id="B143-ijms-22-09118"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhood</surname><given-names>B.</given-names></name><name><surname>Mortezaee</surname><given-names>K.</given-names></name><name><surname>Goradel</surname><given-names>N.H.</given-names></name><name><surname>Khanlarkhani</surname><given-names>N.</given-names></name><name><surname>Salehi</surname><given-names>E.</given-names></name><name><surname>Nashtaei</surname><given-names>M.S.</given-names></name><name><surname>Najafi</surname><given-names>M.</given-names></name><name><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><fpage>5728</fpage><lpage>5740</lpage><pub-id pub-id-type="doi">10.1002/jcp.27442</pub-id><?supplied-pmid 30317564?><pub-id pub-id-type="pmid">30317564</pub-id></element-citation></ref><ref id="B144-ijms-22-09118"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saneja</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Mintoo</surname><given-names>M.J.</given-names></name><name><surname>Dubey</surname><given-names>R.D.</given-names></name><name><surname>Sangwan</surname><given-names>P.L.</given-names></name><name><surname>Mondhe</surname><given-names>D.M.</given-names></name><name><surname>Panda</surname><given-names>A.K.</given-names></name><name><surname>Gupta</surname><given-names>P.N.</given-names></name></person-group><article-title>Gemcitabine and betulinic acid co-encapsulated PLGA&#x02212;PEG polymer nanoparticles for improved efficacy of cancer chemotherapy</article-title><source>Mater. Sci. Eng. C</source><year>2019</year><volume>98</volume><fpage>764</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.01.026</pub-id><?supplied-pmid 30813082?><pub-id pub-id-type="pmid">30813082</pub-id></element-citation></ref><ref id="B145-ijms-22-09118"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>J.</given-names></name><name><surname>Luwor</surname><given-names>R.B.</given-names></name><name><surname>Ahmed</surname><given-names>N.</given-names></name><name><surname>Escalona</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>F.H.</given-names></name><name><surname>Fong</surname><given-names>C.</given-names></name><name><surname>Ratcliffe</surname><given-names>J.</given-names></name><name><surname>Scoble</surname><given-names>J.A.</given-names></name><name><surname>Drummond</surname><given-names>C.J.</given-names></name><name><surname>Tran</surname><given-names>N.</given-names></name></person-group><article-title>Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer</article-title><source>ACS Appl. Mater. Interfaces</source><year>2018</year><volume>10</volume><fpage>25174</fpage><lpage>25185</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b08125</pub-id><?supplied-pmid 29963859?><pub-id pub-id-type="pmid">29963859</pub-id></element-citation></ref><ref id="B146-ijms-22-09118"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>N.</given-names></name><name><surname>Madni</surname><given-names>A.</given-names></name><name><surname>Balasubramanian</surname><given-names>V.</given-names></name><name><surname>Rehman</surname><given-names>M.</given-names></name><name><surname>Correia</surname><given-names>A.</given-names></name><name><surname>Kashif</surname><given-names>P.M.</given-names></name><name><surname>M&#x000e4;kil&#x000e4;</surname><given-names>E.</given-names></name><name><surname>Salonen</surname><given-names>J.</given-names></name><name><surname>Santos</surname><given-names>H.A.</given-names></name></person-group><article-title>Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>533</volume><fpage>156</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.09.061</pub-id><pub-id pub-id-type="pmid">28963013</pub-id></element-citation></ref><ref id="B147-ijms-22-09118"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy</article-title><source>J. Control. Release</source><year>2019</year><volume>295</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.12.013</pub-id><?supplied-pmid 30586598?><pub-id pub-id-type="pmid">30586598</pub-id></element-citation></ref><ref id="B148-ijms-22-09118"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>M.A.</given-names></name><name><surname>Arif</surname><given-names>M.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Zeenat</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>C.-G.</given-names></name></person-group><article-title>Synthesis and evaluation of pH-sensitive, self-assembled chitosan-based nanoparticles as efficient doxorubicin carriers</article-title><source>J. Biomater. Appl.</source><year>2017</year><volume>31</volume><fpage>1182</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1177/0885328216681184</pub-id><pub-id pub-id-type="pmid">28081668</pub-id></element-citation></ref><ref id="B149-ijms-22-09118"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X.-H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>H.J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Spewak</surname><given-names>M.B.</given-names></name><name><surname>Mao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles</article-title><source>ACS Nano</source><year>2011</year><volume>5</volume><fpage>9480</fpage><lpage>9493</lpage><pub-id pub-id-type="doi">10.1021/nn202410f</pub-id><?supplied-pmid 22032622?><pub-id pub-id-type="pmid">22032622</pub-id></element-citation></ref><ref id="B150-ijms-22-09118"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Miao</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Satterlee</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>W.Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model</article-title><source>J. Control. Release</source><year>2014</year><volume>182</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.03.016</pub-id><pub-id pub-id-type="pmid">24637468</pub-id></element-citation></ref><ref id="B151-ijms-22-09118"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Arvizo</surname><given-names>R.R.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Robertson</surname><given-names>D.J.</given-names></name><name><surname>McMeekin</surname><given-names>S.</given-names></name><name><surname>Bhattacharya</surname><given-names>R.</given-names></name><name><surname>Mukherjee</surname><given-names>P.</given-names></name></person-group><article-title>Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>6453</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.2203</pub-id><pub-id pub-id-type="pmid">25071019</pub-id></element-citation></ref><ref id="B152-ijms-22-09118"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauf</surname><given-names>N.</given-names></name><name><surname>Nawaz</surname><given-names>A.</given-names></name><name><surname>Ullah</surname><given-names>H.</given-names></name><name><surname>Ullah</surname><given-names>R.</given-names></name><name><surname>Nabi</surname><given-names>G.</given-names></name><name><surname>Ullah</surname><given-names>A.</given-names></name><name><surname>Wahab</surname><given-names>F.</given-names></name><name><surname>Jahan</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Therapeutic effects of chitosan-embedded vitamin C, E nanoparticles against cisplatin-induced gametogenic and androgenic toxicity in adult male rats</article-title><source>Environ. Sci. Pollut. Res.</source><year>2021</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s11356-021-14516-y</pub-id></element-citation></ref><ref id="B153-ijms-22-09118"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Dou</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>Q.</given-names></name></person-group><article-title>Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>885</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1021/mp400547u</pub-id><pub-id pub-id-type="pmid">24483832</pub-id></element-citation></ref><ref id="B154-ijms-22-09118"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo</article-title><source>Asian J. Pharm. Sci.</source><year>2017</year><volume>12</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2017.04.002</pub-id><pub-id pub-id-type="pmid">32104354</pub-id></element-citation></ref><ref id="B155-ijms-22-09118"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>T.</given-names></name><name><surname>Affram</surname><given-names>K.</given-names></name><name><surname>Nottingham</surname><given-names>E.L.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Amissah</surname><given-names>F.</given-names></name><name><surname>Krishnan</surname><given-names>S.</given-names></name><name><surname>Trevino</surname><given-names>J.</given-names></name><name><surname>Agyare</surname><given-names>E.</given-names></name></person-group><article-title>Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-73218-6</pub-id><pub-id pub-id-type="pmid">31913322</pub-id></element-citation></ref><ref id="B156-ijms-22-09118"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Mu</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>S.</given-names></name></person-group><article-title>Acid-triggered release of native gemcitabine conjugated in polyketal nanoparticles for enhanced anticancer therapy</article-title><source>Biomacromolecules</source><year>2020</year><volume>21</volume><fpage>803</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.9b01493</pub-id><pub-id pub-id-type="pmid">31995366</pub-id></element-citation></ref><ref id="B157-ijms-22-09118"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>T.E.</given-names></name><name><surname>Ilbasmis-Tamer</surname><given-names>S.</given-names></name><name><surname>Takka</surname><given-names>S.</given-names></name></person-group><article-title>Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>580</volume><fpage>119246</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119246</pub-id><?supplied-pmid 32205141?><pub-id pub-id-type="pmid">32205141</pub-id></element-citation></ref><ref id="B158-ijms-22-09118"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Dou</surname><given-names>H.J.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Fei</surname><given-names>X.C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Janin</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>W.L.</given-names></name></person-group><article-title>Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>5673</fpage><lpage>5683</lpage><pub-id pub-id-type="doi">10.2147/IJN.S161203</pub-id><?supplied-pmid 30288040?><pub-id pub-id-type="pmid">30288040</pub-id></element-citation></ref><ref id="B159-ijms-22-09118"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Yin</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Dou</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name></person-group><article-title>Dextran-based fluorescent nanoprobes for sentinel lymph node mapping</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>8227</fpage><lpage>8235</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.06.012</pub-id><?supplied-pmid 24957293?><pub-id pub-id-type="pmid">24957293</pub-id></element-citation></ref><ref id="B160-ijms-22-09118"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuvier</surname><given-names>C.</given-names></name><name><surname>Roblot-Treupel</surname><given-names>L.</given-names></name><name><surname>Millot</surname><given-names>J.</given-names></name><name><surname>Lizard</surname><given-names>G.</given-names></name><name><surname>Chevillard</surname><given-names>S.</given-names></name><name><surname>Manfait</surname><given-names>M.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name><name><surname>Poupon</surname><given-names>M.</given-names></name></person-group><article-title>Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance</article-title><source>Biochem. Pharmacol.</source><year>1992</year><volume>44</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(92)90443-M</pub-id><pub-id pub-id-type="pmid">1354963</pub-id></element-citation></ref><ref id="B161-ijms-22-09118"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;mati</surname><given-names>F.</given-names></name><name><surname>Dubernet</surname><given-names>C.</given-names></name><name><surname>Fessi</surname><given-names>H.</given-names></name><name><surname>de Verdiere</surname><given-names>A.C.</given-names></name><name><surname>Poupon</surname><given-names>M.</given-names></name><name><surname>Puisieux</surname><given-names>F.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name></person-group><article-title>Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer</article-title><source>Int. J. Pharm.</source><year>1996</year><volume>138</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(96)04559-0</pub-id></element-citation></ref><ref id="B162-ijms-22-09118"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Verdiere</surname><given-names>A.C.</given-names></name><name><surname>Dubernet</surname><given-names>C.</given-names></name><name><surname>Nemati</surname><given-names>F.</given-names></name><name><surname>Soma</surname><given-names>E.</given-names></name><name><surname>Appel</surname><given-names>M.</given-names></name><name><surname>Ferte</surname><given-names>J.</given-names></name><name><surname>Bernard</surname><given-names>S.</given-names></name><name><surname>Puisieux</surname><given-names>F.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name></person-group><article-title>Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action</article-title><source>Br. J. Cancer</source><year>1997</year><volume>76</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/bjc.1997.362</pub-id><?supplied-pmid 9231919?><pub-id pub-id-type="pmid">9231919</pub-id></element-citation></ref><ref id="B163-ijms-22-09118"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vlerken</surname><given-names>L.E.</given-names></name><name><surname>Duan</surname><given-names>Z.</given-names></name><name><surname>Seiden</surname><given-names>M.V.</given-names></name><name><surname>Amiji</surname><given-names>M.M.</given-names></name></person-group><article-title>Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>4843</fpage><lpage>4850</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1648</pub-id><?supplied-pmid 17510414?><pub-id pub-id-type="pmid">17510414</pub-id></element-citation></ref><ref id="B164-ijms-22-09118"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>W.</given-names></name><name><surname>Ding</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>T.</given-names></name><name><surname>An</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>G.</given-names></name></person-group><article-title>Intracellular self-assembly of Taxol nanoparticles for overcoming multidrug resistance</article-title><source>Angew. Chem. Int. Ed.</source><year>2015</year><volume>54</volume><fpage>9700</fpage><lpage>9704</lpage><pub-id pub-id-type="doi">10.1002/anie.201504329</pub-id><?supplied-pmid 26118539?><pub-id pub-id-type="pmid">26118539</pub-id></element-citation></ref><ref id="B165-ijms-22-09118"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shuai</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name></person-group><article-title>DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells</article-title><source>J. Mater. Chem. B</source><year>2020</year><volume>8</volume><fpage>1157</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1039/C9TB02130B</pub-id><pub-id pub-id-type="pmid">31951231</pub-id></element-citation></ref><ref id="B166-ijms-22-09118"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>C.-F.</given-names></name><name><surname>Cui</surname><given-names>F.</given-names></name><name><surname>Yin</surname><given-names>Y.-M.</given-names></name><name><surname>Cho</surname><given-names>H.-J.</given-names></name><name><surname>Kim</surname><given-names>D.-D.</given-names></name></person-group><article-title>Docetaxel-loaded chitosan-cholesterol conjugate-based self-assembled nanoparticles for overcoming multidrug resistance in cancer cells</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>783</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12090783</pub-id></element-citation></ref><ref id="B167-ijms-22-09118"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zheng</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nanohybrids for overcoming multidrug resistance of breast cancer cells</article-title><source>Carbohydr. Polym.</source><year>2021</year><volume>251</volume><fpage>117008</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.117008</pub-id><pub-id pub-id-type="pmid">33142574</pub-id></element-citation></ref><ref id="B168-ijms-22-09118"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>The approved gene therapy drugs worldwide: From 1998 to 2019</article-title><source>Biotechnol. Adv.</source><year>2020</year><volume>40</volume><fpage>107502</fpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.107502</pub-id><pub-id pub-id-type="pmid">31887345</pub-id></element-citation></ref><ref id="B169-ijms-22-09118"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Abdelnabi</surname><given-names>A.</given-names></name><name><surname>Maguire</surname><given-names>C.</given-names></name><name><surname>Doha</surname><given-names>M.</given-names></name><name><surname>Sagers</surname><given-names>J.</given-names></name><name><surname>Lewis</surname><given-names>R.</given-names></name><name><surname>Muzikansky</surname><given-names>A.</given-names></name><name><surname>Giovannini</surname><given-names>M.</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>A.</given-names></name><name><surname>Stankovic</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo</article-title><source>Neuro-Oncol.</source><year>2019</year><volume>21</volume><fpage>854</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noz065</pub-id><pub-id pub-id-type="pmid">30977509</pub-id></element-citation></ref><ref id="B170-ijms-22-09118"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Hotta</surname><given-names>A.</given-names></name></person-group><article-title>Genetic correction using engineered nucleases for gene therapy applications</article-title><source>Dev. Growth Differ.</source><year>2014</year><volume>56</volume><fpage>63</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/dgd.12107</pub-id><pub-id pub-id-type="pmid">24329887</pub-id></element-citation></ref><ref id="B171-ijms-22-09118"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>Y.</given-names></name><name><surname>Horng</surname><given-names>J.</given-names></name><name><surname>Perry</surname><given-names>N.</given-names></name><name><surname>Schultz</surname><given-names>H.</given-names></name><name><surname>Iyer</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Aryee</surname><given-names>M.</given-names></name><name><surname>Pinello</surname><given-names>L.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name></person-group><article-title>Augmenting and directing long-range CRISPR-mediated activation in human cells</article-title><source>Nat. Methods</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41592-021-01224-1</pub-id></element-citation></ref><ref id="B172-ijms-22-09118"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>S.</given-names></name><name><surname>Rosenecker</surname><given-names>J.</given-names></name></person-group><article-title>Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems</article-title><source>Gene Ther.</source><year>2017</year><volume>24</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/gt.2017.5</pub-id><pub-id pub-id-type="pmid">28094775</pub-id></element-citation></ref><ref id="B173-ijms-22-09118"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Dagnaes-Hansen</surname><given-names>F.</given-names></name><name><surname>Nielsen</surname><given-names>E.J.</given-names></name><name><surname>Wengel</surname><given-names>J.</given-names></name><name><surname>Besenbacher</surname><given-names>F.</given-names></name><name><surname>Howard</surname><given-names>K.A.</given-names></name><name><surname>Kjems</surname><given-names>J.</given-names></name></person-group><article-title>The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice</article-title><source>Mol. Ther.</source><year>2009</year><volume>17</volume><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.91</pub-id><?supplied-pmid 19401674?><pub-id pub-id-type="pmid">19401674</pub-id></element-citation></ref><ref id="B174-ijms-22-09118"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>B.</given-names></name></person-group><article-title>Branched Antisense and siRNA Co-Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy</article-title><source>Angew. Chem.</source><year>2021</year><volume>133</volume><fpage>1881</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1002/ange.202011174</pub-id></element-citation></ref><ref id="B175-ijms-22-09118"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>N.</given-names></name></person-group><article-title>Dual MicroRNA-triggered drug release system for combined chemotherapy and gene therapy with logic operation</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>32493</fpage><lpage>32502</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c09494</pub-id><pub-id pub-id-type="pmid">32573191</pub-id></element-citation></ref><ref id="B176-ijms-22-09118"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guevara</surname><given-names>M.L.</given-names></name><name><surname>Persano</surname><given-names>F.</given-names></name><name><surname>Persano</surname><given-names>S.</given-names></name></person-group><article-title>Advances in lipid nanoparticles for mRNA-based cancer immunotherapy</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><fpage>963</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.589959</pub-id></element-citation></ref><ref id="B177-ijms-22-09118"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>J.</given-names></name><name><surname>Nair</surname><given-names>A.</given-names></name><name><surname>Veerappan</surname><given-names>S.</given-names></name><name><surname>Sen</surname><given-names>D.</given-names></name></person-group><article-title>Translatable gene therapy for lung cancer using Crispr CAS9&#x02014;An exploratory review</article-title><source>Cancer Gene Ther.</source><year>2020</year><volume>27</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41417-019-0116-8</pub-id><pub-id pub-id-type="pmid">31222183</pub-id></element-citation></ref><ref id="B178-ijms-22-09118"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Progress in arginine-based gene delivery systems</article-title><source>J. Mater. Chem. B</source><year>2020</year><volume>8</volume><fpage>5564</fpage><lpage>5577</lpage><pub-id pub-id-type="doi">10.1039/D0TB00498G</pub-id><pub-id pub-id-type="pmid">32496488</pub-id></element-citation></ref><ref id="B179-ijms-22-09118"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>D.M.</given-names></name><name><surname>Shodeinde</surname><given-names>A.B.</given-names></name><name><surname>Peppas</surname><given-names>N.A.</given-names></name></person-group><article-title>Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2100350</fpage><pub-id pub-id-type="doi">10.1002/adhm.202100350</pub-id></element-citation></ref><ref id="B180-ijms-22-09118"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>J.</given-names></name><name><surname>Rui</surname><given-names>Y.</given-names></name><name><surname>Kozielski</surname><given-names>K.L.</given-names></name><name><surname>Placone</surname><given-names>A.L.</given-names></name><name><surname>Choi</surname><given-names>O.</given-names></name><name><surname>Tzeng</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Keyes</surname><given-names>J.J.</given-names></name><name><surname>Bogorad</surname><given-names>M.I.</given-names></name><name><surname>Gabrielson</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><fpage>20045</fpage><lpage>20057</lpage><pub-id pub-id-type="doi">10.1039/C9NR04795F</pub-id><pub-id pub-id-type="pmid">31612183</pub-id></element-citation></ref><ref id="B181-ijms-22-09118"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.Q.</given-names></name><name><surname>Yu</surname><given-names>Q.L.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>Yu</surname><given-names>H.J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Highly efficient photocontrolled targeted delivery of siRNA by a cyclodextrin-based supramolecular nanoassembly</article-title><source>Chem. Commun.</source><year>2020</year><volume>56</volume><fpage>3907</fpage><lpage>3910</lpage><pub-id pub-id-type="doi">10.1039/D0CC00629G</pub-id></element-citation></ref><ref id="B182-ijms-22-09118"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroll</surname><given-names>A.V.</given-names></name><name><surname>Fang</surname><given-names>R.H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>C.L.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Luk</surname><given-names>B.T.</given-names></name><name><surname>Dehaini</surname><given-names>D.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity</article-title><source>Adv. Mater.</source><year>2017</year><volume>29</volume><fpage>1703969</fpage><pub-id pub-id-type="doi">10.1002/adma.201703969</pub-id></element-citation></ref><ref id="B183-ijms-22-09118"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name></person-group><article-title>Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2019</year><volume>47</volume><fpage>1635</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1608219</pub-id><?supplied-pmid 31027450?><pub-id pub-id-type="pmid">31027450</pub-id></element-citation></ref><ref id="B184-ijms-22-09118"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>B.</given-names></name></person-group><article-title>Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer</article-title><source>Nano Res.</source><year>2019</year><volume>12</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1007/s12274-019-2308-9</pub-id><pub-id pub-id-type="pmid">31737223</pub-id></element-citation></ref><ref id="B185-ijms-22-09118"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Tao</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name></person-group><article-title>Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>590</volume><fpage>119963</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119963</pub-id><pub-id pub-id-type="pmid">33039492</pub-id></element-citation></ref><ref id="B186-ijms-22-09118"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izadi</surname><given-names>S.</given-names></name><name><surname>Moslehi</surname><given-names>A.</given-names></name><name><surname>Kheiry</surname><given-names>H.</given-names></name><name><surname>Kiani</surname><given-names>F.K.</given-names></name><name><surname>Ahmadi</surname><given-names>A.</given-names></name><name><surname>Masjedi</surname><given-names>A.</given-names></name><name><surname>Ghani</surname><given-names>S.</given-names></name><name><surname>Rafiee</surname><given-names>B.</given-names></name><name><surname>Karpisheh</surname><given-names>V.</given-names></name><name><surname>Hajizadeh</surname><given-names>F.</given-names></name></person-group><article-title>Codelivery of HIF-1&#x003b1; siRNA and dinaciclib by carboxylated graphene oxide-trimethyl chitosan-hyaluronate nanoparticles significantly suppresses cancer cell progression</article-title><source>Pharm. Res.</source><year>2020</year><volume>37</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s11095-020-02892-y</pub-id><?supplied-pmid 32944844?><pub-id pub-id-type="pmid">32944844</pub-id></element-citation></ref><ref id="B187-ijms-22-09118"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Mao</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Cell-selective messenger RNA delivery and CRISPR/Cas9 genome editing by modulating the interface of phenylboronic acid-derived lipid nanoparticles and cellular surface sialic acid</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>46585</fpage><lpage>46590</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b17749</pub-id><?supplied-pmid 31763806?><pub-id pub-id-type="pmid">31763806</pub-id></element-citation></ref><ref id="B188-ijms-22-09118"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Hang</surname><given-names>Y.</given-names></name><name><surname>Jaramillo</surname><given-names>L.</given-names></name><name><surname>Wehrkamp</surname><given-names>C.J.</given-names></name><name><surname>Phillippi</surname><given-names>M.A.</given-names></name><name><surname>Mohr</surname><given-names>A.M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Talmon</surname><given-names>G.A.</given-names></name></person-group><article-title>Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>4305</fpage><pub-id pub-id-type="doi">10.7150/thno.26506</pub-id><pub-id pub-id-type="pmid">30214622</pub-id></element-citation></ref><ref id="B189-ijms-22-09118"><label>189.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Couzin-Frankel</surname><given-names>J.</given-names></name></person-group><source>Cancer Immunotherapy</source><publisher-name>American Association for the Advancement of Science</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B190-ijms-22-09118"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillman</surname><given-names>R.O.</given-names></name></person-group><article-title>Cancer immunotherapy</article-title><source>Cancer Biother. Radiopharm.</source><year>2011</year><volume>26</volume><fpage>1</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1089/cbr.2010.0902</pub-id><pub-id pub-id-type="pmid">21355777</pub-id></element-citation></ref><ref id="B191-ijms-22-09118"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Abdou</surname><given-names>P.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Mo</surname><given-names>R.</given-names></name></person-group><article-title>Advances in engineering cells for cancer immunotherapy</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>7889</fpage><pub-id pub-id-type="doi">10.7150/thno.38583</pub-id><pub-id pub-id-type="pmid">31695806</pub-id></element-citation></ref><ref id="B192-ijms-22-09118"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>D.J.</given-names></name><name><surname>Wolchok</surname><given-names>J.D.</given-names></name><name><surname>Rosenberg</surname><given-names>L.M.</given-names></name><name><surname>Girotra</surname><given-names>M.</given-names></name></person-group><article-title>Cancer immunotherapy&#x02014;Immune checkpoint blockade and associated endocrinopathies</article-title><source>Nat. Rev. Endocrinol.</source><year>2017</year><volume>13</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2016.205</pub-id><pub-id pub-id-type="pmid">28106152</pub-id></element-citation></ref><ref id="B193-ijms-22-09118"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.-M.</given-names></name></person-group><article-title>Adoptive cell transfer: Is it a promising immunotherapy for colorectal cancer?</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>5784</fpage><pub-id pub-id-type="doi">10.7150/thno.29035</pub-id><pub-id pub-id-type="pmid">30555581</pub-id></element-citation></ref><ref id="B194-ijms-22-09118"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modak</surname><given-names>S.</given-names></name><name><surname>Le Luduec</surname><given-names>J.-B.</given-names></name><name><surname>Cheung</surname><given-names>I.Y.</given-names></name><name><surname>Goldman</surname><given-names>D.A.</given-names></name><name><surname>Ostrovnaya</surname><given-names>I.</given-names></name><name><surname>Doubrovina</surname><given-names>E.</given-names></name><name><surname>Basu</surname><given-names>E.</given-names></name><name><surname>Kushner</surname><given-names>B.H.</given-names></name><name><surname>Kramer</surname><given-names>K.</given-names></name><name><surname>Roberts</surname><given-names>S.S.</given-names></name></person-group><article-title>Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study</article-title><source>Oncoimmunology</source><year>2018</year><volume>7</volume><fpage>e1461305</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1461305</pub-id><?supplied-pmid 30221057?><pub-id pub-id-type="pmid">30221057</pub-id></element-citation></ref><ref id="B195-ijms-22-09118"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies</article-title><source>Clin. Immunol.</source><year>2020</year><volume>214</volume><fpage>108382</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108382</pub-id><?supplied-pmid 32169439?><pub-id pub-id-type="pmid">32169439</pub-id></element-citation></ref><ref id="B196-ijms-22-09118"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.-Y.</given-names></name><name><surname>Fan</surname><given-names>M.H.</given-names></name><name><surname>Miao</surname><given-names>C.H.</given-names></name><name><surname>Liao</surname><given-names>Y.J.</given-names></name><name><surname>Yuan</surname><given-names>R.-H.</given-names></name><name><surname>Liu</surname><given-names>C.L.</given-names></name></person-group><article-title>Engineering chimeric antigen receptor T cells against immune checkpoint inhibitors PD-1/PD-L1 for treating pancreatic cancer</article-title><source>Mol. Ther.-Oncolytics</source><year>2020</year><volume>17</volume><fpage>571</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2020.05.009</pub-id><?supplied-pmid 32637575?><pub-id pub-id-type="pmid">32637575</pub-id></element-citation></ref><ref id="B197-ijms-22-09118"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>e2000845</fpage><pub-id pub-id-type="doi">10.1002/adhm.202000845</pub-id><pub-id pub-id-type="pmid">32790039</pub-id></element-citation></ref><ref id="B198-ijms-22-09118"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>A.M.E.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Fadlallah</surname><given-names>G.M.</given-names></name><name><surname>Gauthier</surname><given-names>M.</given-names></name><name><surname>Ouyang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer</article-title><source>Adv. Sci. (Weinh)</source><year>2020</year><volume>7</volume><fpage>1903164</fpage><pub-id pub-id-type="doi">10.1002/advs.201903164</pub-id><?supplied-pmid 32440473?><pub-id pub-id-type="pmid">32440473</pub-id></element-citation></ref><ref id="B199-ijms-22-09118"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahzad</surname><given-names>K.A.</given-names></name><name><surname>Naeem</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wan</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Pei</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name></person-group><article-title>Design and optimization of PLGA particles to deliver immunomodulatory drugs for the prevention of skin allograft rejection</article-title><source>Immunol. Investig.</source><year>2020</year><volume>49</volume><fpage>840</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1080/08820139.2019.1695134</pub-id><?supplied-pmid 31809611?><pub-id pub-id-type="pmid">31809611</pub-id></element-citation></ref><ref id="B200-ijms-22-09118"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>A.</given-names></name><name><surname>Mangel</surname><given-names>L.</given-names></name><name><surname>Fijuth</surname><given-names>J.</given-names></name><name><surname>&#x0017b;urawski</surname><given-names>B.</given-names></name><name><surname>Ursulovic</surname><given-names>T.</given-names></name><name><surname>Nikolin</surname><given-names>B.</given-names></name><name><surname>Djan</surname><given-names>I.</given-names></name><name><surname>Olson</surname><given-names>J.G.</given-names></name></person-group><article-title>Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen</article-title><source>Eur. J. Cancer</source><year>2020</year><volume>138</volume><fpage>S35</fpage><pub-id pub-id-type="doi">10.1016/S0959-8049(20)31164-3</pub-id></element-citation></ref><ref id="B201-ijms-22-09118"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugisaka</surname><given-names>J.</given-names></name><name><surname>Sugawara</surname><given-names>S.</given-names></name><name><surname>Toi</surname><given-names>Y.</given-names></name><name><surname>Ogasawara</surname><given-names>T.</given-names></name><name><surname>Aso</surname><given-names>M.</given-names></name><name><surname>Tsurumi</surname><given-names>K.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Domeki</surname><given-names>Y.</given-names></name><name><surname>Aiba</surname><given-names>T.</given-names></name></person-group><article-title>Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>ix112</fpage><lpage>ix113</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz438.018</pub-id></element-citation></ref><ref id="B202-ijms-22-09118"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passariello</surname><given-names>M.</given-names></name><name><surname>Camorani</surname><given-names>S.</given-names></name><name><surname>Vetrei</surname><given-names>C.</given-names></name><name><surname>Ricci</surname><given-names>S.</given-names></name><name><surname>Cerchia</surname><given-names>L.</given-names></name><name><surname>De Lorenzo</surname><given-names>C.</given-names></name></person-group><article-title>Ipilimumab and its derived EGFR aptamer-based conjugate induce efficient NK cell activation against cancer cells</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>331</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12020331</pub-id><?supplied-pmid 32024070?><pub-id pub-id-type="pmid">32024070</pub-id></element-citation></ref><ref id="B203-ijms-22-09118"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naves</surname><given-names>L.B.</given-names></name><name><surname>Dhand</surname><given-names>C.</given-names></name><name><surname>Venugopal</surname><given-names>J.R.</given-names></name><name><surname>Rajamani</surname><given-names>L.</given-names></name><name><surname>Ramakrishna</surname><given-names>S.</given-names></name><name><surname>Almeida</surname><given-names>L.</given-names></name></person-group><article-title>Nanotechnology for the treatment of melanoma skin cancer</article-title><source>Prog. Biomater.</source><year>2017</year><volume>6</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s40204-017-0064-z</pub-id><?supplied-pmid 28303522?><pub-id pub-id-type="pmid">28303522</pub-id></element-citation></ref><ref id="B204-ijms-22-09118"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>T.</given-names></name><name><surname>Shiraishi</surname><given-names>H.</given-names></name><name><surname>Fujiwara</surname><given-names>Y.</given-names></name></person-group><article-title>Durvalumab for the treatment of PD-L1 non-small cell lung cancer</article-title><source>Expert Rev. Precis. Med. Drug Dev.</source><year>2021</year><volume>6</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1080/23808993.2021.1855075</pub-id></element-citation></ref><ref id="B205-ijms-22-09118"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awasthi</surname><given-names>R.</given-names></name><name><surname>Pacaud</surname><given-names>L.</given-names></name><name><surname>Waldron</surname><given-names>E.</given-names></name><name><surname>Tam</surname><given-names>C.</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>U.</given-names></name><name><surname>Borchmann</surname><given-names>P.</given-names></name><name><surname>Jaglowski</surname><given-names>S.</given-names></name><name><surname>Foley</surname><given-names>S.</given-names></name><name><surname>van Besien</surname><given-names>K.</given-names></name><name><surname>Wagner-Johnston</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>560</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000525</pub-id><pub-id pub-id-type="pmid">32045475</pub-id></element-citation></ref><ref id="B206-ijms-22-09118"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>S.I.</given-names></name><name><surname>Ju</surname><given-names>X.</given-names></name><name><surname>Horvath</surname><given-names>L.</given-names></name><name><surname>Clark</surname><given-names>G.J.</given-names></name></person-group><article-title>Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>562</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.641307</pub-id></element-citation></ref><ref id="B207-ijms-22-09118"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habibi</surname><given-names>N.</given-names></name><name><surname>Christau</surname><given-names>S.</given-names></name><name><surname>Ochyl</surname><given-names>L.J.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Hassani Najafabadi</surname><given-names>A.</given-names></name><name><surname>Kuehnhammer</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Helgeson</surname><given-names>M.</given-names></name><name><surname>Klitzing</surname><given-names>R.</given-names></name><name><surname>Moon</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Engineered Ovalbumin Nanoparticles for Cancer Immunotherapy</article-title><source>Adv. Ther.</source><year>2020</year><volume>3</volume><pub-id pub-id-type="doi">10.1002/adtp.202000100</pub-id></element-citation></ref><ref id="B208-ijms-22-09118"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi</surname><given-names>N.</given-names></name><name><surname>Swiston</surname><given-names>A.J.</given-names></name><name><surname>Gilbert</surname><given-names>J.B.</given-names></name><name><surname>Alcaraz</surname><given-names>M.L.</given-names></name><name><surname>Cohen</surname><given-names>R.E.</given-names></name><name><surname>Rubner</surname><given-names>M.F.</given-names></name><name><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group><article-title>Cell-based drug delivery devices using phagocytosis-resistant backpacks</article-title><source>Adv. Mater.</source><year>2011</year><volume>23</volume><fpage>H105</fpage><lpage>H109</lpage><pub-id pub-id-type="doi">10.1002/adma.201004074</pub-id><pub-id pub-id-type="pmid">21365691</pub-id></element-citation></ref><ref id="B209-ijms-22-09118"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>J.</given-names></name><name><surname>Shao</surname><given-names>S.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy</article-title><source>Small</source><year>2016</year><volume>12</volume><fpage>5108</fpage><lpage>5119</lpage><pub-id pub-id-type="doi">10.1002/smll.201601282</pub-id><pub-id pub-id-type="pmid">27560388</pub-id></element-citation></ref><ref id="B210-ijms-22-09118"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochyl</surname><given-names>L.J.</given-names></name><name><surname>Bazzill</surname><given-names>J.D.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Kuai</surname><given-names>R.</given-names></name><name><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>182</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.08.016</pub-id><pub-id pub-id-type="pmid">30121425</pub-id></element-citation></ref><ref id="B211-ijms-22-09118"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>H.</given-names></name><name><surname>Lai</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>G.</given-names></name></person-group><article-title>Surface-Layer Protein-Enhanced Immunotherapy Based on Cell Membrane-Coated Nanoparticles for the Effective Inhibition of Tumor Growth and Metastasis</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>9850</fpage><lpage>9859</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b00294</pub-id><pub-id pub-id-type="pmid">30788951</pub-id></element-citation></ref><ref id="B212-ijms-22-09118"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>P.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name></person-group><article-title>Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>12096</fpage><lpage>12108</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b05292</pub-id><pub-id pub-id-type="pmid">30444351</pub-id></element-citation></ref><ref id="B213-ijms-22-09118"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Suo</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.-T.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name></person-group><article-title>Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect</article-title><source>Biochim. Et Biophys. Acta-Rev. Cancer</source><year>2018</year><volume>1870</volume><fpage>51</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2018.06.005</pub-id><?supplied-pmid 29959989?><pub-id pub-id-type="pmid">29959989</pub-id></element-citation></ref><ref id="B214-ijms-22-09118"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>T.</given-names></name><name><surname>Tong</surname><given-names>P.</given-names></name><name><surname>Stewart</surname><given-names>C.A.</given-names></name><name><surname>Cristea</surname><given-names>S.</given-names></name><name><surname>Valliani</surname><given-names>A.</given-names></name><name><surname>Shames</surname><given-names>D.S.</given-names></name><name><surname>Redwood</surname><given-names>A.B.</given-names></name><name><surname>Fan</surname><given-names>Y.H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Glisson</surname><given-names>B.S.</given-names></name></person-group><article-title>CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>3870</fpage><lpage>3884</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3409</pub-id><pub-id pub-id-type="pmid">28490518</pub-id></element-citation></ref><ref id="B215-ijms-22-09118"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Fu</surname><given-names>P.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name></person-group><article-title>Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: A multi-institutional retrospective analysis</article-title><source>Cancer Chemother. Pharmacol.</source><year>2020</year><volume>86</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s00280-020-04091-3</pub-id><pub-id pub-id-type="pmid">32533335</pub-id></element-citation></ref><ref id="B216-ijms-22-09118"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Teng</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Nanogel-Incorporated Injectable Hydrogel for Synergistic Therapy Based on Sequential Local Delivery of Combretastatin-A4 Phosphate (CA4P) and Doxorubicin (DOX)</article-title><source>ACS Appl. Mater. Interfaces</source><year>2018</year><volume>10</volume><fpage>18560</fpage><lpage>18573</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b04394</pub-id><pub-id pub-id-type="pmid">29767951</pub-id></element-citation></ref><ref id="B217-ijms-22-09118"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Drug delivery systems for differential release in combination therapy</article-title><source>Expert Opin. Drug Deliv.</source><year>2011</year><volume>8</volume><fpage>171</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1517/17425247.2011.547470</pub-id><pub-id pub-id-type="pmid">21226651</pub-id></element-citation></ref><ref id="B218-ijms-22-09118"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Thambi</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>D.S.</given-names></name></person-group><article-title>Co-delivery of drugs and genes using polymeric nanoparticles for synergistic cancer therapeutic effects</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>1700886</fpage><pub-id pub-id-type="doi">10.1002/adhm.201700886</pub-id></element-citation></ref><ref id="B219-ijms-22-09118"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>pH-Responsive charge switchable PEGylated epsilon-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment</article-title><source>J Control. Release</source><year>2020</year><volume>326</volume><fpage>350</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.030</pub-id><pub-id pub-id-type="pmid">32707209</pub-id></element-citation></ref><ref id="B220-ijms-22-09118"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Duan</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Biodegradable Nanoscale Coordination Polymers for Targeted Tumor Combination Therapy with Oxidative Stress Amplification</article-title><source>Adv. Funct. Mater.</source><year>2020</year><volume>30</volume><fpage>1908865</fpage><pub-id pub-id-type="doi">10.1002/adfm.201908865</pub-id></element-citation></ref><ref id="B221-ijms-22-09118"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name></person-group><article-title>An efficient delivery of photosensitizers and hypoxic prodrugs for a tumor combination therapy by membrane camouflage nanoparticles</article-title><source>J. Mater. Chem. B</source><year>2020</year><volume>8</volume><fpage>2876</fpage><lpage>2886</lpage><pub-id pub-id-type="doi">10.1039/D0TB00235F</pub-id><pub-id pub-id-type="pmid">32191252</pub-id></element-citation></ref><ref id="B222-ijms-22-09118"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Di</surname><given-names>W.</given-names></name></person-group><article-title>Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>3325</fpage><lpage>3339</lpage><pub-id pub-id-type="doi">10.7150/thno.41228</pub-id><pub-id pub-id-type="pmid">32194871</pub-id></element-citation></ref><ref id="B223-ijms-22-09118"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.K.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Lillard</surname><given-names>J.W.</given-names><suffix>Jr.</suffix></name><name><surname>Singh</surname><given-names>R.</given-names></name></person-group><article-title>Drug delivery approaches for breast cancer</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>6205</fpage><pub-id pub-id-type="doi">10.2147/IJN.S140325</pub-id></element-citation></ref><ref id="B224-ijms-22-09118"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persano</surname><given-names>F.</given-names></name><name><surname>Gigli</surname><given-names>G.</given-names></name><name><surname>Leporatti</surname><given-names>S.</given-names></name></person-group><article-title>Lipid-polymer hybrid nanoparticles in cancer therapy: Current overview and future directions</article-title><source>Nano Express</source><year>2021</year><volume>2</volume><fpage>012006</fpage><pub-id pub-id-type="doi">10.1088/2632-959X/abeb4b</pub-id></element-citation></ref><ref id="B225-ijms-22-09118"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Jin</surname><given-names>G.</given-names></name><name><surname>Kang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>2405</fpage><pub-id pub-id-type="doi">10.2147/IJN.S161426</pub-id></element-citation></ref><ref id="B226-ijms-22-09118"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>Y.</given-names></name></person-group><article-title>Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>590</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.10.009</pub-id><pub-id pub-id-type="pmid">24125775</pub-id></element-citation></ref><ref id="B227-ijms-22-09118"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>8483</fpage><pub-id pub-id-type="doi">10.2147/IJN.S148359</pub-id></element-citation></ref><ref id="B228-ijms-22-09118"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>P.</given-names></name><name><surname>Miyata</surname><given-names>K.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Cabral</surname><given-names>H.</given-names></name></person-group><article-title>Clinical translation of self-assembled cancer nanomedicines</article-title><source>Adv. Ther.</source><year>2021</year><volume>4</volume><fpage>2000159</fpage><pub-id pub-id-type="doi">10.1002/adtp.202000159</pub-id></element-citation></ref><ref id="B229-ijms-22-09118"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Applications of molybdenum oxide nanomaterials in the synergistic diagnosis and treatment of tumor</article-title><source>Appl. Nanosci.</source><year>2020</year><volume>10</volume><fpage>2069</fpage><lpage>2083</lpage><pub-id pub-id-type="doi">10.1007/s13204-020-01389-9</pub-id></element-citation></ref><ref id="B230-ijms-22-09118"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallury</surname><given-names>P.</given-names></name><name><surname>Malhotra</surname><given-names>A.</given-names></name><name><surname>Byrne</surname><given-names>L.M.</given-names></name><name><surname>Santra</surname><given-names>S.</given-names></name></person-group><article-title>Nanobioimaging and sensing of infectious diseases</article-title><source>Adv. Drug Del. Rev.</source><year>2010</year><volume>62</volume><fpage>424</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2009.11.014</pub-id></element-citation></ref><ref id="B231-ijms-22-09118"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;rian</surname><given-names>J.</given-names></name><name><surname>Gravier</surname><given-names>J.</given-names></name><name><surname>Navarro</surname><given-names>F.</given-names></name><name><surname>Texier</surname><given-names>I.</given-names></name></person-group><article-title>Fluorescent nanoprobes dedicated to in vivo imaging: From preclinical validations to clinical translation</article-title><source>Molecules</source><year>2012</year><volume>17</volume><fpage>5564</fpage><lpage>5591</lpage><pub-id pub-id-type="doi">10.3390/molecules17055564</pub-id><pub-id pub-id-type="pmid">22576228</pub-id></element-citation></ref><ref id="B232-ijms-22-09118"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napp</surname><given-names>J.</given-names></name><name><surname>Mathejczyk</surname><given-names>J.E.</given-names></name><name><surname>Alves</surname><given-names>F.</given-names></name></person-group><article-title>Optical imaging in vivo with a focus on paediatric disease: Technical progress, current preclinical and clinical applications and future perspectives</article-title><source>Pediatric Radiol.</source><year>2011</year><volume>41</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/s00247-010-1907-0</pub-id></element-citation></ref><ref id="B233-ijms-22-09118"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollrath</surname><given-names>A.</given-names></name><name><surname>Schubert</surname><given-names>S.</given-names></name><name><surname>Schubert</surname><given-names>U.S.</given-names></name></person-group><article-title>Fluorescence imaging of cancer tissue based on metal-free polymeric nanoparticles&#x02014;A review</article-title><source>J. Mater. Chem. B</source><year>2013</year><volume>1</volume><fpage>1994</fpage><lpage>2007</lpage><pub-id pub-id-type="doi">10.1039/c3tb20089b</pub-id><pub-id pub-id-type="pmid">32260887</pub-id></element-citation></ref><ref id="B234-ijms-22-09118"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisch</surname><given-names>A.</given-names></name><name><surname>Klymchenko</surname><given-names>A.S.</given-names></name></person-group><article-title>Fluorescent polymer nanoparticles based on dyes: Seeking brighter tools for bioimaging</article-title><source>Small</source><year>2016</year><volume>12</volume><fpage>1968</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1002/smll.201503396</pub-id><pub-id pub-id-type="pmid">26901678</pub-id></element-citation></ref><ref id="B235-ijms-22-09118"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klymchenko</surname><given-names>A.S.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Collot</surname><given-names>M.</given-names></name><name><surname>Anton</surname><given-names>N.</given-names></name></person-group><article-title>Dye-Loaded Nanoemulsions: Biomimetic Fluorescent Nanocarriers for Bioimaging and Nanomedicine</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2001289</fpage><pub-id pub-id-type="doi">10.1002/adhm.202001289</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-22-09118-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The different types of polymer nanocarriers-based drug delivery for cancer therapeutics [<xref rid="B136-ijms-22-09118" ref-type="bibr">136</xref>,<xref rid="B137-ijms-22-09118" ref-type="bibr">137</xref>].</p></caption><graphic xlink:href="ijms-22-09118-g001"/></fig><fig id="ijms-22-09118-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy Reproduced from Song et al. [<xref rid="B111-ijms-22-09118" ref-type="bibr">111</xref>].</p></caption><graphic xlink:href="ijms-22-09118-g002"/></fig><table-wrap id="ijms-22-09118-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-22-09118-t001_Table 1</object-id><label>Table 1</label><caption><p>List of polymer NPs for Cancer Chemotherapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Nanocarriers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taxol (PTX)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-assembled lipid NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, ovary, and lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-ijms-22-09118" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folex (Methotrexate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid-polymer hybrid NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, lung, blood, bone, and lymph system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-ijms-22-09118" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adriamycin (Dox)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA NPs and chitosan NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer, lymphoma, and multiple myeloma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-ijms-22-09118" ref-type="bibr">147</xref>,<xref rid="B148-ijms-22-09118" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platinol-AQ (Cisplatin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ScFvEGFR-heparin-cisplatin;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bladder, ovary, lung, and testicles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-ijms-22-09118" ref-type="bibr">149</xref>,<xref rid="B150-ijms-22-09118" ref-type="bibr">150</xref>,<xref rid="B151-ijms-22-09118" ref-type="bibr">151</xref>,<xref rid="B152-ijms-22-09118" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncovin (Vincristine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide R7-conjugated PLGA-PEG NPs;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leukemia and lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-ijms-22-09118" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-FU (Fluorouracil)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan NPs and solid lipid NPs;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon, breast, stomach, and head and neck</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-ijms-22-09118" ref-type="bibr">154</xref>,<xref rid="B155-ijms-22-09118" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemzar (Gemcitabine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyketal NPs and lipid polymer hybrid;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas, breast, ovary, and lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-ijms-22-09118" ref-type="bibr">156</xref>,<xref rid="B157-ijms-22-09118" ref-type="bibr">157</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-22-09118-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-22-09118-t002_Table 2</object-id><label>Table 2</label><caption><p>List of polymer NPs in gene therapy for cancer treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NPs (Class)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA (P53)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel amino lipid NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B184-ijms-22-09118" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA (CDK1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aptamer-protamine-siRNA NPs and Carboxylated graphene oxide-trimethyl chitosan-hyaluronate NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer, melanoma, and colorectal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B185-ijms-22-09118" ref-type="bibr">185</xref>,<xref rid="B186-ijms-22-09118" ref-type="bibr">186</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRISPR/Cas9 genome editing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenylboronic acid-derived lipid NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B187-ijms-22-09118" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miRNA (c-Myc)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">polymeric CXCR4 antagonists NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human malignant cholangiocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-ijms-22-09118" ref-type="bibr">188</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-22-09118-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-22-09118-t003_Table 3</object-id><label>Table 3</label><caption><p>NPs-based immunotherapy for cancer treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class of Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Keytruda (Pembrolizumab)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Checkpoint Inhibitor<break/>(PD-1 inhibitor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma and non&#x02013;small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-ijms-22-09118" ref-type="bibr">200</xref>,<xref rid="B201-ijms-22-09118" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yervoy (Ipilimumab)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Checkpoint Inhibitor<break/>(CTLA-4 inhibitor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-ijms-22-09118" ref-type="bibr">202</xref>,<xref rid="B203-ijms-22-09118" ref-type="bibr">203</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Imfinzi (Durvalumab)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Checkpoint Inhibitor<break/>(PD-L1 inhibitor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-ijms-22-09118" ref-type="bibr">204</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kymriah (Tisagenlecleucel)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAR T-cell therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Large B-cell lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B205-ijms-22-09118" ref-type="bibr">205</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Provenge (Sipuleucel-T)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B206-ijms-22-09118" ref-type="bibr">206</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-22-09118-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-22-09118-t004_Table 4</object-id><label>Table 4</label><caption><p>List of polymer NPs for combination therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Agents</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NPs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel/lonidamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymeric PLGA-PEG NPs, PCL NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B223-ijms-22-09118" ref-type="bibr">223</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX/combretastatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid-polymer hybrid NPs, PLGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B216-ijms-22-09118" ref-type="bibr">216</xref>,<xref rid="B224-ijms-22-09118" ref-type="bibr">224</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOX/metformin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folic acid-cholesterolsodium alginate NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-ijms-22-09118" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTX/siRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">layer-by-layer NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B225-ijms-22-09118" ref-type="bibr">225</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SiRNA/OVA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B226-ijms-22-09118" ref-type="bibr">226</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>